programme book - the voice of medtech in asia · following the success of last year’s medtech...

PROGRAMME BOOK

8 TH – 10 TH NOVEMBER CREAT ING NEW PARTNERSHIP IN HEALTHCARE

#APMTF2016

ii

Suntec Singapore Convention & Exhibition Centre8th – 10th November 2016 | Singapore

1


TABLE OF CONTENTS

WELCOME MESSAGE ........…………………………………………………………………………… 3

CONFERENCE INFORMATION ………………………………………………………………………… 4

EXHIBITION FLOORPLAN ....…………………………………………………………………………… 7

INNOVATION SHOWCASE FLOOR PLAN .......................................................................... 8

INNOVATION SHOWCASE HIGHLIGHTS ........................................................................... 9

SCHEDULE OF INNOVATION SHOWCASE MED-TALKS ..................................................... 10

CONFERENCE PROGRAMME ………………………………………………………………………… 12

SESSION SYNOPSIS ....................................................................................................... 18

GALA DINNER ............................................................................................................... 23

ASIA PACIFIC MEDTECH FORUM 2016 SPEAKERS BIOGRAPHY ......................................... 25

SPONSOR LISTING ...........…………………………………………………………………………… 53

2


References: 1. http://www.sciencedirect.com/science/article/pii/S0002939402021104 ©2016 Novartis 9/16 1609I01A

REIMAGINING EYE CARE

@AlconEyeCare

@Alcon

CONNECT WITH US!

Learn more at www.alcon.com

Alcon’s mission is to discover new ways to enhance sight and improve people’s lives, and we have done this successfully for 70 years. Our products touch the lives of millions of people each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

We have firsthand experience working in developing markets where loss of sight means loss of productivity, loss of community connection. We know that by reducing the number of blind individuals to 24 million people globally by 2020, the economic gain could be $102 billion.1

Reimagining eye care means to us that we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world.

3


Dear Friends and Colleagues,

These are exciting but challenging times for our industry in Asia Pacific. Demand for quality healthcare in the region continues to soar and outstrip supply – driven by an ageing population, a rapidly growing middle class and the rise of chronic, non-communicable diseases such as cardiovascular disease, cancer, diabetes and chronic respiratory disease.

Advances in medical devices, equipment and in vitro diagnostics play an important role in addressing these challenges. But technology alone is not sufficient. All stakeholders in our ecosystem need to work together, sometimes in new creative ways, to bring new approaches to prevention, diagnosis and treatment of disease to all patient groups.

Following the success of last year’s MedTech Forum, the Asia Pacific Medical Technology Association (APACMed) is delighted to welcome you to the Asia Pacific MedTech Forum 2016 at Suntec City Convention Centre on 8-10 November.

We will bring together senior industry leaders, clinicians, patients, hospital CEO’s, government policy makers, payers and other stakeholders from around the globe, all looking to transform the healthcare sector and raise standards of care across Asia Pacific. The Forum provides exceptional opportunities to network, share best practices, and discuss and advance cutting edge initiatives.

This is without a doubt the medical technology industry’s most impactful gathering of people and ideas in the region.

Please join us at the Asia Pacific MedTech Forum 2016, to create new partnerships in healthcare!Yours Sincerely,

Fredrik NybergChief Executive OfficerAsia Pacific Medical Technology Association (APACMed)

WELCOME MESSAGE FROM THE CHIEF EXECUTIVE OFFICER

References: 1. http://www.sciencedirect.com/science/article/pii/S0002939402021104 ©2016 Novartis 9/16 1609I01A

REIMAGINING EYE CARE

@AlconEyeCare

@Alcon

CONNECT WITH US!

Learn more at www.alcon.com

Alcon’s mission is to discover new ways to enhance sight and improve people’s lives, and we have done this successfully for 70 years. Our products touch the lives of millions of people each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

We have firsthand experience working in developing markets where loss of sight means loss of productivity, loss of community connection. We know that by reducing the number of blind individuals to 24 million people globally by 2020, the economic gain could be $102 billion.1

Reimagining eye care means to us that we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world.

4


CONFERENCE INFORMATION

Conference VenueSuntec Singapore Convention & Exhibition Centre1 Raffles Boulevard, Suntec CitySingapore 039593

Registration DeskSuntec Singapore Convention & Exhibition Centre, Level 4, Hall 406/405

Opening hours are as follow:Tuesday, 8 November 2016 08:00 – 18:00hrsWednesday, 9 November 2016 07:30 – 16:45hrs

Exhibition Opening Dates & TimingSuntec Singapore Convention & Exhibition Centre, Level 4, Hall 406/405Tuesday, 8 November 2016 09:00 – 18:00hrsWednesday, 9 November 2016 09:00 – 16:30hrs

On-Site PaymentOn-Site payment can be made only by cash (SGD) or by credit cards (Visa or Mastercard) at the registration counters.

Category Onsite RateAPACMed Member1 SGD1,500Non-Members2 SGD1,950Government/Academia3 SGD1,050Gala Dinner TicketClifford PierThe Fullerton Bay Hotel Singapore

SGD95

1. Applicable to participants from member companies. Registration must be made from a member company e-mail domain.2. Please note that non-members can only attend sessions on 8 – 9 November 2016.3. Applicable to participants with official email domains (e.g. .gov or .edu)

Conference BadgesConference Badges are required for admission to all sessions and official functions. Registered delegates are requested to wear badges at all times for identification and security purposes.

In the event of a lost or forgotten badge, a replacement fee of SGD80 will be applicable for reprint of the badge. Reprinting can be done at the registration desk, upon presentation of registration number or confirmation letter.

Lunch / Coffee Break InformationLunch/Coffee breaks will be available at the Level 4, Hall 406/405.

Speakers InformationAll invited speakers must report two hours before their presentation or the day before to check/deposit their presentations at the faculty registration desk located on Level 4, Hall 406/405.

Opening hours of the faculty registration desk are as follow:Tuesday, 8 November 2016 08:00 – 17:00hrsWednesday, 9 November 2016 08:00 – 17:00hrs

Conference Dress CodeBusiness wear

5


Download Asia Pacific MedTech Forum 2016 to navigate your way around the conference! Use the app to plan your days, find out about last-minute changes, and network with fellow attendees.

The Asia Pacific MedTech Forum 2016 mobile app includes:

• Full interactive agenda• Latest news and info about the forum• Speaker list with detailed bios• Maps of the convention centre• List of exhibitors• Photo wall• Downloadable presentations• Daily schedule updates and more...

Official Conference hashtag #APMTF2016

6


7


EXHIBITION FLOORPLAN

EXITENTRANCE /

REG

ISTR

ATIO

N

REG

ISTR

ATIO

N

ALCON

&ONJOHNS

ONJOHNS

MEDTRONIC

TERUMO

B. BRAUN

ZIMMER

BISTRO TABLE

BISTRO TABLE

COFFEE BREAK 2(LUNCH AREA)

DELOITTE

PLENARY HALL

LUNCH AREA

TERUMOTERUMO

QUINTILES

UPS

RESEARCHINC

INNOVATION SHOWCASE

BostonScientific

A20

EXHIBITOR LISTINGAlcon A13B. Braun A11Boston Scientific A20Deloitte A18INC research A1Johnson & Johnson A6

Medtronic A15 QuintilesIMS A4 Terumo A2 UPS A2 Zimmer Biomet A25

8


INNOVATION SHOWCASE FLOORPLAN

EXITENTRANCE /

FD

REG

ISTR

ATIO

N

REG

ISTR

ATIO

N

ALCON

&ONJOHNS

ONJOHNS

MEDTRONIC

TERUMO

B. BRAUN

ZIMMER

BISTRO TABLE

BISTRO TABLE

COFFEE BREAK 2(LUNCH AREA)

21 OCTOBER 2016

This design is the property of Pico andcannot be copied or modified wholly orpartially without Pico's prior written con-sent. This drawing is subject to modifi-cation to suit construction purpose.

Remarks

--

Date Submitted

Drawing Title

GENERAL LAYOUTHALL 405,406

Design UnitDESIGN STUDIO

Client Project /Event Event Period

Venue

Customer Service PersonTEO YUE YING

Technical DesignerKRYSTAL

Drawing Number

Scale1:250 (A3 SIZE)

Approval Signature

Design Director

Client

--

--

- SUNTEC SINGAPORE,HALL 405-406

APAC MEDTECHFORUM 2016 PICO/2016/176/A101

08-10 NOVEMBER 2016, SUNTEC SINGAPORE, HALL 405-406APAC MEDTECH FORUM 2016 NORMAL

DELOITTE

PLENARY HALL

LUNCH AREA

TERUMOTERUMO

QUINTILES

UPS

RESEARCHINC

APACMedBDMYDOC

B.BRAUN BSC

CALIGNER ADVENT

STRYKERINNOV-FUSION

INNOVATIONSHOWCASE

TIMELINESCREEN

BARDHOLMUSKHEALINTAV CONSOLE

TERUMO

STA

GE

BostonScientific

A20

INNOVATION SHOWCASE

Medical technology companies create lifesaving and life changing innovations. These medical devices and diagnostics allow people to live longer, healthier and more productive lives.

The Innovation Showcase allows selected companies to demonstrate their latest innovative products and services dedicated booths.

Advent Booth 9Bard Booth 10B. Braun Booth 6BD Booth 5

BSC Booth 7Caligner Booth 8Healint Booth 12Holmusk Booth 11

Innovfusion Booth 1MyDoc Booth 4Stryker Booth 2Terumo Booth 3

INNOVATOR LISTING

APACMed

9


INNOVATION SHOWCASE HIGHLIGHTS

No. Company Highlights

1 Terumo Corporation Regenerative Medicine: Autologous cell therapy product to treat severe, ischemic heart failure patients.

2 Bard Singapore Pte Ltd Targeted Temperature Management

3 StrykerEvidenced based designs for implants 3D printed implants Advanced imaging modalities for minimally invasive surgery

4 Boston Scientific Subcutaneous Implantable Defibrillator (S-ICD)

5 B. Braun One Infusion System for all Therapies

6 BD Blood Collection and Separation Technology

7 Holmusk Digital platform for diabetes management

8 MyDoc Pte Ltd Digital tools for personal management of healthcare

9 Healint Remote monitoring system for management of chronic dis-eases

10 Advent Access Pte. Ltd. Vascular access for haemodialysis- unlocking the future of self-dialysis

11 Caligner Home-based IOT pill dispenser

12 Innovfusion Pte Ltd Smart Infusion System

10


Day 1 Day 2

10:30 - 11:30

10:35 - 10:45 Terumo B. Braun

10:45 - 10:55 Holmusk Caligner

12:30 - 13:30

12:45 - 12:55 C.R. Bard Stryker

12:55 - 13:05 Healint Innovfusion

13:05 - 13:15 Medtronic BD

14:30 - 15:00

14:35 - 14:45 Boston Scientific Medtronic

14:45 - 14:55 Advent Access

SCHEDULE OF INNOVATION SHOWCASE MED-TALKS

11


12


CONGRESS PROGRAMME

DAY 1: TUESDAY, 8TH NOVEMBER 201608:00 - 09:00 Registration (Level 4, Hall 405 406)

09:00 - 09:10Opening Remarks (Level 4, Hall 406CX)• Mr Vladimir Makatsaria, APACMed, Chairman, Company Group Chairman, Johnson & Johnson, Asia Pacific

09:10 - 09:30 Plenary #1: PATIENT STORY – Type I Diabetes (Level 4, Hall 406CX)• Ms. Yoshitaa Jayabalan (Malaysia)

09:30 - 10:30

Plenary #2: Global Leadership Dialogue – The Evolving Role of Asia Pacific on the Global Stage. (Level 4, Hall 406CX)Moderated by Mr Martin Dewhurst, Director and Senior Partner, McKinsey’s London office

Panellists:• Mr Koji Nakao, Corporate Adviser And Former Chairman, Terumo Corporation• Mr Gary Pruden, Worldwide Chairman of Medical Devices and Executive Vice President, Johnson &

Johnson.• Ms Anna Maria Braun, President, Asia Pacific & Member of the Management Board, B. Braun

Melsungen AG

10:30 - 11:00 Refreshments and Networking Break (Level 4, Hall 405)Exhibition and Innovation Showcase

11:00 - 11:45Plenary #3a: KEYNOTE - Digital Health – Accelerating Adoption of New Delivery Care Models in Emerging Markets. (Level 4, Hall 406CX)• Dr Rana Dasgupta, Chief Operating Officer, Apollo Hospitals Group

11:45 - 12:30

Plenary #3b: APACMed – McKinsey – Business Sentiment Survey 2016 (Level 4, Hall 406CX)Moderated by Dr. Axel Baur, Senior Partner, Mckinsey’s Tokyo office

Panellists:• Ms Elisabeth Staudinger, President Asia Pacific, Siemens Healthineers• Mr Patrick Holt, President of Medical Products, Cardinal Health Asia Pacific• Mr Hideo Arase, Managing Director, Terumo Asia Holdings Pte. Ltd

12:30 - 13:30 Networking Lunch (Level 4, Hall 405)Exhibition and Innovation Showcase

13:30 - 14:30

Access breakout:The Road to Regulatory Harmonization & Convergence - Progress, Impact and Next Steps.(Level 3, Room 331-332)Moderated by A/Prof John Lim, Deputy Director of Medical Services (Industry & Research Matters), Ministry of Health, Singapore, Executive Director, Centre of Regulatory Excellence,Duke-NUS Graduate Medical School, Singapore, Chairman, Singapore Clinical Research InstitutePanellists:• Dr. Jun Kitahara, Director,

Division of Regulatory Cooperation, Office of International Programs, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

• Dr. Choongman Hong, Director, Department of Medical Device Evaluation, Ministry of Food and Drug Safety, South Korea

• A/Prof Raymond Chua, Group Director, Health Science Authority (HSA)

• Ms Tran Quan, Vice President Regulatory Affairs, APACMed

Innovation breakout:Innovating in Mobile Health: Trends and Opportunities in this Growing Market.(Level 3, Room 330)• Mr Glenn Snyder, Medical Technology Segment Leader, Deloitte’s San Francisco office

Collaboration breakout:Public Private Partnerships Case Studies – Can the MedTech Industry Do More?(Level 3, Room 334- 336)Moderated by Dr. Jeremy Lim, Partner, Head of Health & Life Sciences, Asia Pacific, Oliver Wyman

Panellists:• Dr. Tan Sze Wee, Executive

Director of A*STAR’s Science and Engineering Council (SERC)

• Dr. Joselito Vital, Public Health Consultant, German International Agency

• Mr Chris Colwell, Senior Director, Public Affairs, Greater Asia, Becton Dickinson (BD)

*Information accurate as of 14 November 2016.

13


CONGRESS PROGRAMME

DAY 1: TUESDAY, 8TH NOVEMBER 2016


15:00 - 16:00

Plenary #4: Lancet Commission on Global Surgery – Panel Update on the “Global Surgery 2030” Report (Level 4, Hall 406CX)Moderated by Dr. Ross D. Segan, Chief Medical Officer, Medical Devices, Global Medical Affairs, Research and Development, Johnson & Johnson

Panellists:• Prof. Russell L. Gruen, Vice-Dean (Research) & Professor of Surgery, Lee Kong Chian School of

Medicine (NTU)• Dr. Jaymie Claire Ang Henry, Founding Executive Director, Global Alliance for Surgical, Obstetric,

Trauma, and Anaesthesia Care (G4)• Dr. William P. Magee, CEO and Co-Founder, Operation Smile

16:00 - 17:00

Access breakout:“Global Surgery 2030” – The Role of the MedTech Industry in Solving this Challenge.(Level 3, Room 331-332)Moderated by Dr. Ross D. Segan, Chief Medical Officer, Medical Devices, Global Medical Affairs, Research and Development, Johnson & Johnson

Panellists:• Prof. Russell L. Gruen, Vice-

Dean (Research) & Professor of Surgery, Lee Kong Chian School of Medicine (NTU)

• Ms Erin Barringer, Associate Partner, Dalberg Global Development Advisors and Director, Safe Surgery 2020

• Mr Paul Smith, Marketing Director, GE Healthcare Asia Pacific

Innovation breakout:The Era of HealthTech - Harnessing its Potential to Fundamentally Impact Standards of Care in Asia.(Level 3, Room 330)Moderated by Dr. Ronald Ling, Co-Founder and Director, Galen Growth Asia

Panellists:• Mr Nawal Roy, Founder and

CEO, Holmusk• Dr. Zubin Daruwalla, Director,

PricewaterhouseCooper (PwC) South East Asia Consulting

• Mr Michel Birnbaum, Entrepreneur-in-Residence, NTUitive

• Mr Hareesh Nair, Director, Quadria Capital

Collaboration breakout:Legal Compliance Developments – How the Industry-HCP Relationship is Changing.(Level 3, Room 334- 336)Moderated by Mr Christopher L. White, Chief Operating Officer, General Counsel and Secretary, Advanced Medical Technology Association (AdvaMed)

Panellists:• Mr Richard Hamilton, Chief

Legal Counsel, International Stryker Corporation

• Mr Campbell Clark, Chief Ethics & Compliance Officer, Asia Pacific, Medtronic

• Mr Benjamin Kwak, Vice President, Compliance Officer & Senior Legal Counsel, Asia Pacific, Zimmer Biomet

• Mr Lok Mun Leng, Deputy Director, Group Procurement Office, SingHealth

18:30 - 21:00 GALA DINNER (Admission by separate ticket)Clifford Pier, The Fullerton Bay Hotel, Singapore


14


CONGRESS PROGRAMME

DAY 2: WEDNESDAY, 9TH NOVEMBER 2016

08:00 - 09:00 Executive Breakfast Dialogue Session(Sponsored; by invitation only)

09:00 - 09:05 Opening Remarks (Level 4, Hall 406CX)

09:05 - 09:25Plenary #5a: PATIENT STORY - Impact of Innovation (Level 4, Hall 406CX)• Dr. Paul Ong Jau Lueng, Senior Consultant Cardiologist and Director of Invasive Cardiac Laboratory in

the Department of Cardiology

09:25 - 09:45

Plenary #5b: Consensus Statement on the Future of Medical Device Registries Across Asia-Pacific and Middle East-North Africa. (Level 4, Hall 406CX)• Mr Fredrik Nyberg, CEO, APACMed• Mr Simranjit Singh, Senior Director of Strategic Planning and General Manager, Medical Devices and

Diagnostics, Asia Pacific, QuintilesIMS

09:45 - 10:30

Plenary #6: Engaging Through Change Leadership through Organizational Disruption in MedTech. (Level 4, Hall 406CX)Moderated by Ms Gladdy He, Senior Client Partner, Korn Ferry’s Shanghai office

Panellists:• Mr James Lim, Executive Vice President and President, Greater Asia of Becton Dickinson (BD)• Mr Brent Scott, President, Stryker Asia Region• Ms Lorraine Parker-Clegg, Vice President, Human Resources, Asia-Pacific, Medtronic• Mr Haresh Khoobchandani, General Manager, Microsoft Business solution APAC


11:00 - 11:45Plenary #7a: Creating Access to Safe Surgery through Innovative Partnerships (Level 4, Hall 406CX)• Dr. William P. Magee, CEO and Co-Founder, Operation Smile

11:45 - 12:30

Plenary #7b: Medical Education & Capacity Building in Asia – What can Industry Do to Accelerate Change? (Level 4, Hall 406CX)Moderated by Mr Pavan Choudary, DG & Chairman, Medical Technology Association of India (MTal)

Panellists:• Prof. Robert Kamei, Associate Provost (Education) and Director, Institute for Application of Learning

Science and Educational Technology (ALSET), National University of Singapore (NUS)• Dr. Sherry Keramidas, Founder and CEO MindfuLeadership• Dato’ Dr Jacob Thomas, Group Medical Advisor, Ramsay Sime Darby Health Care and President,

Association of Private Hospitals of Malaysia (APHM)• Mr Jose (Pepe) Calle Gordo, CEO, Biosensors International Group

12:30 - 13:30 Networking Lunch (Level 4, Hall 405)Exhibition and Innovation Showcase


15


CONGRESS PROGRAMME

DAY 2: WEDNESDAY, 9TH NOVEMBER 2016

13:30 - 14:30

Access breakout:Does Universal Health Care (UHC) Improve Access to Medical Technology?(Level 3, Room 331 - 332)Moderated by Dr. Claudia Süssmuth Dyckerhoff, Senior External Advisor, McKinsey

Panellists:• Ms Ong Ai Hua, President,

ONE Johnson & Johnson Southeast Asia

• Ms Putty Kartika, Country Director, Medtronic Indonesia

• Dr. Joselito Vital, Public Health Consultant, German International Agency

• Mr Stanley Su, President, B. Braun China

Innovation breakout:Developing Market-Appropriate Products for Emerging Economies.(Level 3, Room 330)Moderated by Ms Yan Lin Lye, Business Development Manager, Cambridge Consultants

Panellists:• Mr Bassam Jabry, Managing

Director, Chemistry• Mr Matt Durack, Senior

Design Director, Lunar Design Singapore

• Dr. Dirk Biskup, Co-Founder and Managing Director, Center for Genomics and Transcriptomics (CeGaT)

• Mr Bruno Occhipinti, Director of Strategy and New Business Development, Philips Healthcare Asia Pacific

Collaboration breakout:The Evolving Role of Medical Affairs in the Medical Technology Industry. (Level 3, Room 334 - 336)Moderated by Dr. Amar Kureishi, Head, Clinical & Regulatory Affairs for Region Asia/Russia, Alcon

Panellists:• Dr. Ross D. Segan, Chief

Medical Officer, Medical Devices, Global Medical Affairs, Research and Development, Johnson & Johnson

• Dr. Amit Shanker, Chief Medical Officer, Asia Pacific, Middle East & Africa, Boston Scientific

• Dr. Michael Etter, Senior Vice President Medical Affairs, Chief Medical Officer Asia Pacific, Fresenius Medical Care


15:00 - 15:45

Plenary #8: Innovative Healthcare Delivery Models in Emerging Markets (Level 4, Hall 406CX)Moderated by Dr. Hunter Cherwek, Medical Director- Strategic Markets, Alcon Laboratories

Panellists:• Dr. Elesh Kumar Jain, Consultant, Public Health, Hospital Administrator and Consultant, Paediatric

Ophthalmology, India• Dr. Mahbubur Chowdhury, Chairman, Bangladesh Eye Hospital

15:45 - 16:30

Plenary #9: Looking ahead: Working Together to Raise Standards of Care in Asia Pacific. (Level 4, Hall 406CX)Moderated by Mr Jake Henry, Managing Partner, McKinsey’s Chicago office

Panellists:• Mr Supratim Bose, Executive Vice President and President, Asia-Pacific, Middle East & Africa, Boston

Scientific,• Mr Stephen Ooi, Senior Executive Advisor, Zimmer Biomet• Mr Harvinder Singh, Divisional Vice President, Asia Pacific and Japan, Abbott Vascular

16:30 - 16:45 Closing remarks (Level 4, Hall 406CX)• Mr Fredrik Nyberg, CEO, APACMed


16


CONGRESS PROGRAMME

DAY 3: THURSDAY, 10TH NOVEMBER 2016

09:00 - 17:00Legal and Compliance Meeting Asia Pacific 2016Open only to APACMed, AdvaMed, MTAA and MTANZ member companies.Separate registration is required.

Description:

Following the success of the last few years’ legal and compliance best practices exchanges, APACMed along with AdvaMed (Advanced Medical Technology Association), MTAA (Medical Technology Association of Australia) and MTANZ (Medical Technology Association of New Zealand) will jointly organize and host a meeting for the Associations’ member company legal professionals to discuss current compliance trends and share best practices in addressing the region’s unique legal and compliance issues.

Venue: Suntec Singapore Convention & Exhibition Centre, Level 3, Room 330

DAY 3: THURSDAY, 10TH NOVEMBER 2016

09:00 - 17:15

APACMed Regulatory Affairs Summit – Building Regulatory Capacity for Medical Devices in Asia PacificOpen only to regulators, academia and APACMed member companies.Separate registration is required.

Description:

This hands on meeting, bringing together regulators and industry experts, aims to address the challenge of regulatory capacity building for medical devices throughout the region.

The group will discuss a number of critical issues, including : Considerations for building professional capacity in Asia, benchmarking these against approaches in other regions; Regulatory models and frameworks that can be used as a blueprint to build professional capacity and address needs in the region; Key competency areas for regulators and industry and Immediate and longer term priorities

A white paper summarising the conclusions and recommendations will be drafted on behalf of APACMed

Venue: Suntec Singapore Convention & Exhibition Centre, Level 3, Room 333


17


IN THE TIME IT TOOK YOU TO READ THIS SENTENCE, SIX MORE LIVES WERE IMPROVED

UC201602657 EN © 2015 Medtronic. All Rights Reserved. Printed in USA 09/2015

Each year, Medtronic helps alleviate pain, restore

health and extend lives for millions of people around

the world. In fact, two people every second are

positively impacted by our breadth of medical

technologies and therapies.

Because every second counts.

Learn more at medtronic.com/furthertogether.

18


SESSIONS SYNOPSIS

Plenary #1:PATIENT STORY – Type I Diabetes

During this session, a 26-year old medical student from Malaysia shares her inspirational story of managing and living with Type 1 Diabetes. She will share her personal journey including how medical technology has improved her quality of living and her aspirations to drive awareness around better disease management options.

Plenary #2: Global Leadership Dialogue – The Evolving Role of Asia Pacific on the Global Stage

This panel of global healthcare leaders will discuss the context, opportunities and challenges in Asia Pacific healthcare and how its potential can be unlocked over the next 10 years:

The relevance of Asia Pacific in the global context for the healthcare sector

• The significant growth opportunities and unique challenges of Asia Pacific from the perspective of global healthcare leaders

• The opportunity for health systems in Asia Pacific to leapfrog their Western counterparts

How engagement with patients is evolving in Asia Pacific

• Key actions in Asia Pacific over the next 5-10 years that will unlock the potential of the growth market

• How MedTech companies should evolve to unlock their potential• How industry collaboration can evolve to resolve some of these challenges, and what

areas APACMed should focus on

Plenary #3a: KEYNOTE – Digital Health – Accelerating Adoption of New Delivery Care Models in Emerging Markets.

Ms. Sangita Reddy is Joint Managing Director at Apollo Hospitals Group, the largest hospital network in Asia with more than 9,000 beds in 44 locations. With responsibilities that involve policy, growth and strategy, Ms. Reddy is pivotal in directing the group’s operations.

In addition, under her stewardship the Apollo Hospitals in Hyderabad has emerged as Asia’s first Health City. It has done so by introducing multi-dimensional holistic healthcare to India.

Ms. Reddy is a member of the World Economic Forum’s Global Agenda Council on Digital Health which aims to advance the use, adoption and measurement of technology in health and healthcare, focusing on digital health. She has greatly influenced the development of the healthcare information technology industry in India, particularly with the global Healthcare IT Conferences that she had initiated in 2010. An ardent champion advocating the benefits of a global delivery model through rural hospitals, outreach camps, telemedicine and other such innovative models, Ms. Reddy has always been focused on the need to create healthcare of the future. She spearheaded the organization’s endeavors in the domain of telemedicine, e-health and mobile health and continues to head the IT functions across all divisions of the Apollo Hospitals Group.

Plenary #3b: APACMed – McKinsey – Business Sentiment Survey 2016

In this panel, Asia Pacific leaders in medical technology will discuss the new findings and implications from the latest APACMed Business Sentiment Survey, to arrive at actions mov-ing forward.

Building on the 3 key levers for delivering the Asia Pacific MedTech promise and the 3 areas for industry-wide collaborations that McKinsey called for last year, McKinsey and APACMed has followed up with ~130 executives in APAC from ~20 MNC MedTech com-panies via a “Business Sentiment Survey”, to shed the lights on current situations along 6 dimensions, namely:

• Organizing to win, including autonomy, talent and capability• Offering market appropriate portfolio to capture opportunities in new patient segments• Commercial model evolvement from scale expansion to more sophisticated model• Intensified regulatory environment, challenges and resolutions• Re-thinking of professional education in today’s technology context• New healthcare delivery paradigm with innovative settings of care

SESSIONS SYNOPSIS

19


Access breakout: The Road to Regulatory Harmonization & Convergence – Progress, Impact and Next Steps.

This session brings together representatives from regulatory authorities and the MedTech industry to share their perspectives on initiatives to promote greater regulatory harmoniza-tion and convergence around the Asia Pacific. They will give their assessments of what has been accomplished over the past twenty years through regional groupings such as APEC and ASEAN, and the work of the Asian Harmonization Working Party and the Interna-tional Medical Device Regulators Forum. The panel will also speak on issues that still need to be addressed and the way ahead to further promote harmonization and convergence of regional medical device regulatory systems in the next 5-10 years.

Innovation breakout: Innovating in Mobile Health: Trends and Opportunities in this Growing Market.

The med tech industry has met its next growth engine – mHealth. By harnessing the ex-ponential power of mobile technologies, data and analytics, mHealth is anticipated to disrupt traditional health care delivery models and drive innovation across the health care continuum. We will discuss: what is mHealth, its impact on the patient journey, how it helps drive innovation, explore opportunities for collaboration, identify the common barriers to adoption, look at the potential implications and opportunities for med tech and assess mHealth in emerging markets.

Collaboration breakout:

Public Private Partnerships Case Studies – Can the MedTech Industry Do More?

Public-private partnerships in health combine the knowledge and resources of different organizations in innovative ways to help participants achieve goals more efficiently or achieve goals that may not be attainable working individually. Advantages of engaging in partnerships to achieve goals include: leveraging resources to achieve goals more ef-ficiently; maximizing the relative strengths of each partner and filling gaps in expertise; reducing risks for each partner; accelerating the time for results; and piloting or demon-strating new ideas on a small scale to evaluate their potential benefit on a larger scale.

There is no one model for public-private partnerships, and they can be tailored according to the goals of the parties involved. This panel will discuss case studies of different partner-ships and explore areas for increased collaboration.

Plenary #4: Lancet Commission on Global Surgery – Panel Update on the “Global Surgery 2030” Report

From Lancet Commission to National Surgical Planning and Implementation – Where are we as a global community at providing care to the 5 billion people who lack access to surgery and anesthesia care when needed? What is the role of the MedTech industry in solving this global challenge?

In April of 2015, the Lancet released a special report, “Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development” which was the culmination of over two years of work, involving representatives from all sectors with an interest in surgery and public health from over 110 countries (http://www.thelancet.com/commissions/global-surgery). The report makes a compelling case that lack of access to surgery and anesthesia care is the single largest global public health challenge, greater than all communicable and non-communicable diseases. With 32% of the global burden of disease addressable through surgery and only 6% of the Low-Middle Income Country population having reliable access this is a global imperative. Since the Lancet report, awareness and action globally has accelerated with passage of WHA 68.15 (http://www.who.int/surgery/wha-eb/en/), statements by the World Bank, significant coverage in the scientific and lay literature.

This session aims to detail the progress of the multifaceted work to address this challenge to date and discuss the critical role that a united MedTech industry can actively play. Global insights and case studies will be presented in concert with a focus on the needs, solutions and ongoing work in Asia Pacific.

Access breakout: “Global Surgery 2030” – The Role of the MedTech Industry in Solving this Challenge.

The lack of access to surgical healthcare and anesthesia care is the single largest global public health challenge, greater than all communicable ad non-communicable diseases. Following the plenary session on Global Surgery 2030, this breakout session attempts to create a dialog around the medical technology industry’s critical role and what can be done to address this global challenge.

20


Innovation breakout: The Era of HealthTech - Harnessing its Potential to Fundamentally Impact Standards of Care in Asia.

Healthcare in Asia comes in two flavours. Developed economies face the same woes as other developed economies across the world as they strive to address their ageing populations with chronic diseases at an affordable cost. Developing economies are grap-pling with solving significant health challenges in large populations with immature health systems.

Healthcare has reached an inflexion point where tech’s Moore’s Law is revolutionising the entire value chain. This represents a unique opportunity for Asia to leapfrog itself to signifi-cantly improve the standard care. However, healthcare is complex and many challenges need to be overcome.

In this panel, we will explore the healthtech innovation ecosystem in Asia and reflect on what is going well, what could be done differently and what still needs to be done to suc-ceed.

Collaboration breakout: Legal Compliance Developments – How the Industry-HCP Relationship is Changing.

Collaborative interactions between industry and health care providers (HCP’s) are essential to advancing medical technology and ensuring the safe and effective use of the manufacturers’ products and services. Most major industry associations, including APACMed, are committed to ensuring that these interactions meet the highest ethical standards, preserve HCPs’ independent decision-making, and reinforce public confidence in the integrity of patient care, treatment, and product and service selection.

Codes of Ethics in the medical technology sector have evolved significantly over the last 10 years. Yet the compliance environment remains challenging in many parts of Asia Pacific. In addition, industry business models are changing in response to new government payment and procurement policies. This panel will examine implications of the latest developments in business ethics and global compliance, evolving government procurement and payment policies and incentives, and new business models on the Industry HCP relationship, and how to address specific local commercial challenges.

Plenary #5a: PATIENT STORY - Impact of Innovation

There is no doubt that technology is shifting how physicians and patients communicate with one another. As patients have access to more information at their fingertips, they are becoming increasingly knowledgeable and involved with their healthcare decisions.

This session explores the considerations faced when making life-saving decisions around medical technology innovations through a compelling dialogue between a renowned interventional cardiologist and his patient.

Plenary #5b: Consensus Statement on the Future of Medical Device Registries Across Asia-Pacific and Middle East-North Africa

Registries are a mechanism to collect information about patient populations being treated, the provider’s quality and processes of care, device performance, and the clinical outcomes achieved. If designed and executed properly, a registry can provide useful information about the safety and effectiveness of medical interventions.

Market-specific, readily verifiable, credible data elements acquired from medical device registries are being increasingly utilized by governments across Asia-Pacific in informing regulatory approval, reimbursement, and coverage decisions.

APACMed support principles of evidence-based healthcare. This session will introduce a new APACMed position paper to be published shortly: “Consensus Statement on the Future of Medical Device Registries Across Asia-Pacific & Middle East-North Africa”

Plenary #6: Engaging Through Change - Leadership through Organizational Disruption in MedTech.

In recent years, the Medical technology industry has been experiencing major changes, including numerous merger & acquisitions, corporate restructuring, or a period of slower growth for some segments.

These could all be a response to the disruptive power of digitization, the complexity of globalization, and increasing regulatory pressure. It can also be the constant change that’s part of simply staying afloat in today’s dynamic business environment – let alone ahead. None of this is going away anytime soon.

In this panel session, our Senior Client Partner from Korn Ferry, Gladdy He, will be moderating the discussion with seasoned Medical Technology leaders to share their practical advice and real-life experiences of engaging through change.

Gladdy will also provide the latest Korn Ferry research and related case studies. The outcome, hopefully, could be your guide to driving, managing and measuring change.

21


Plenary #7a: Creating Access to Safe Surgery through Innovative Partnerships

After nearly 35 years of providing safe, well-timed, and effective surgery, Operation Smile has developed the expertise to become a leader in global surgery. In 2015, the United Nations approved the Sustainable Development Goals, paving the way for safe surgery to be addressed at a global level. Operation Smile is poised to begin implementing safe surgical platforms through the use of innovative public and private partnerships around the world, paving the way for Ministries of Health, NGO’s and corporations to begin taking actionable steps to alleviate the burden that exists for the billions of people who lack access to surgical care.

William P. Magee, Jr., D.D.S, M.D, CEO and Co-Founder of Operation Smile, will discuss the many approaches and innovative partnerships needed to create access to safe surgery around the world.

Plenary #7b: Medical Education & Capacity Building in Asia – What can Industry Do to Accelerate Change?

The 2015 McKinsey study “MedTech in Asia” identified physician education and regulatory capacity building as key opportunities for multi-stakeholder collaboration. This session will examine both of these important topics.

The regional shortage of trained healthcare professionals, particularly physicians, has been identified as a significant obstacle to serving larger numbers of patients, especially in emerging markets. The panel will discuss possible collaborative efforts to address this shortage and how technology can be used to transform medical education.

Regulating medical technology is a relatively new mandate for many governments in the region and recruiting regulators with appropriate skills has been challenging. Beyond capacity, Asia-Pacific regulators often struggle to stay abreast of rapid advances in medical technology. In many markets, the responsibility for approving medical devices has fallen on agencies that traditionally have overseen the pharmaceutical industry.

The panel will examine how regulators, academics, healthcare providers, industry executives and trade associations can better collaborate to build regulatory capacity and to accelerate and enhance medical education in Asia Pacific.

Access breakout: Does Universal Health Care (UHC) Improve Access to Medical Technology?

Governments’ efforts to deliver universal healthcare (UHC) have brought many changes to the healthcare landscape. Understanding how UHC affect access to medical technology becomes increasingly critical to win in this evolving market.

The goal of this panel is to understand the UHC situation in three representative markets, China, Indonesia, and Philippines, jointly discuss the outlook of UHC, and derive implications for medical technology, including:

• UHC development roadmap and current stage • How UHC reform has changed the breadth and depth of the coverage of medical

products• Achievements and ongoing challenges in UHC implementation• Discussion with panelist to get local perspectives on UHC outlook, how UHC affects

access, implication to MedTech, and what companies can do to further expand and shape UHC

Innovation breakout: Developing Market-Appropriate Products for Emerging Economies.

To move beyond the premium segment and reach a broader group of patients and healthcare providers, MedTech companies need to develop market-appropriate products and services rooted in innovation that appeal to customers seeking different value propositions. Instead of importing de-featured devices that were successful in Europe and North America, companies are beginning to localize R&D to access a broader segment that seeks better value for money, whether through lower prices, products and services tailored to specific needs, or both.

This panel will examine specific design considerations and provide case examples of how companies have successfully reached underserved patients in the region. Opportunities in personalized medicine and genetic diagnostics will also be addressed.

Collaboration breakout: The Evolving Role of Medi-cal Affairs in the Medical Technology Industry.

While medical affairs is a well-established function within the pharmaceutical industry, it is relatively new to the medical technology industry. This breakout creates a conversation around how and why the role of medical affairs has evolved to play such a central role in pharmaceuticals and what key learnings and lessons can be applied to medical technology.

22


Plenary #8: Innovative Healthcare Delivery Models in Emerging Markets

This session explores how innovative healthcare delivery models can be applied in emerging markets, using successful world-class examples that have expanded into innovative training programs and business models, including:

• Training of nurses, engineers, technicians, and community eye health workers• Standardized and measured surgeon training with long-term clinical and partnership

development in an expanding hospital network

Plenary #9: Looking ahead: Working Together to Raise Standards of Care in Asia Pacific.

The goal of this panel is to discuss what industry can do to raise the standard of care in Asia Pacific. The panelists of Asia Pacific MedTech leaders will first reflect on the current environment, including the opportunities and challenges, then examine and discuss in depth the top five priority areas that needs to be addressed in order to improve the quality of care in Asia Pacific:

• Regulatory advocacy: how can industry work together to have a greater impact on the regulatory agencies?

• Physician education: How can the current training infrastructure be expanded to train more doctors, while also upgrading their capabilities?

• Connecting with gov’t policy makers on access and quality: how can industry leaders and policy-makers better work together to address access and quality of care?

• Driving innovation: How can APAC be turned into a hotbed for innovation, including value segment product, innovative delivery model, and tailored solution?

• Promoting market access to technologies: how will the compliance environment likely to evolve, and what are the priorities for our industry going forward?

23


ASIA PACIFIC MEDTECH FORUM 2016

Gala DinnerTuesday, 8 November 2016

6.30pm – 9.00pmClifford Pier, The Fullerton Bay, Hotel, Singapore

Asia Pacific MedTech Forum’s Gala Dinner is the networking highlight of the Forum. It will be a gathering of delegates, sponsors, partners and key industry players

in an atmosphere of lively good fun.

Reception starts at 6.30pm and Dinner at 7.30pm

RegistrationAll guests who have registered for the gala dinner can retrieve their ticker upon their registration.

TransportationTwo-way transfer will be provided between Suntec Singapore Convention & Exhibition Centre and Clifford Pier.

*Scheduled of transfer will be provided on-site.

Gala Dinner Sponsor

24


At Zimmer Biomet, we pursue possibilities.

It’s our promise to look beyond what’s possible now

and discover what’s possible next.

Every day, we focus on improving musculoskeletal healthcare.

It’s all we do. It’s all we have ever done.

We are committed to working by your side, and to break

through boundaries in pursuit of exceptional patient outcomes.

Visit us on the web at zimmerbiomet.com

©2016 Zimmer Biomet

It’s not just what we make...It’s what we make possible.

Corporate-Runner-Gold Sponsorship-2016 APAC MedTech Event.indd 1 10/28/16 9:31 AM

25


Hideo AraseManaging Director, Terumo Asia Holdings Pte Ltd

Mr. Arase serves as Director & SEO, Regional Representative, India and Asia Pacific, Terumo Corporation and as MD, Terumo Asia Holdings. He takes initiatives to reinforce the governance/compliance/promote the business development of entities in Asian Pacific regions and India. He is a Board Member of APACMED, and based in Singapore.

He has global business experiences with various portfolio in 39 services with Terumo. He served as President/CEO of Terumo Americas Holding, Terumo Medical Brazil, Terumo Corporation and Terumo Europe (2009 -2011). Between 1988-1991, he studied Biodesign Executive Education Management Innovation at Stanford University (2015), Communication Strategies at New York University Leonard N. Stern Business School in 2013, Advanced Coaching Training Program at Leeds Metropolitan University in 2009, and earned MBA with High Honors from United Business Institutes (2001). He has been Awarded for GLOBIS Alumni Award 2010 for Revolution and had Publication for ‘Dangerous Syndrome of Organization’ (Joint Authorship) 1998.

Erin BarringerAssociate Partner, Dalberg Global Development Advisors Director, Safe Surgery 2020

Erin Barringer is an Associate Partner in Dalberg’s New York office and also serves as the Director for Safe Surgery 2020. In her role at Dalberg, she has advised Fortune 500 companies, foundations, governments, and multi-lateral organizations on strategic planning, the design and launch of new initiatives, market entry and growth strategies, and the creation of innovative financing mechanisms. Erin has unique sector experience in global health, including maternal, neonatal, and child health, infectious diseases, and non-communicable diseases. As the Director of Safe Surgery 2020, Erin has led a multi-partner initiative, with seed funding from GE Foundation, which focuses on transforming surgical outcomes in low and middle income countries.

Prior to joining Dalberg, Erin worked at Endeavor Global as a director of Endeavor Insight, and at Acumen Fund as an Investment Associate for healthcare and technology deals. Erin also previously worked at IMS Consulting, providing strategy and market access advice to top pharmaceutical manufacturers and medical device companies around the world. Erin holds a Masters in Business Administration from Harvard Business School and a B.A. from Harvard University (Cum Laude) where she majored in History of Science with minors in Health Policy and Latin American Studies.

Axel BaurSenior Partner, McKinsey’s Tokyo office

Dr Axel Baur is a Senior Partner based in McKinsey’s Japan office, having served previously in Germany and in the Middle East. Previously a co-leader of the Europe and German office Healthcare Practices, he is now the leader of McKinsey’s Asia Healthcare Practice including the Pharmaceutical and Medical Products. He advises top management in pharmaceutical and medical product companies along their entire value chain, and brings experience in the broader healthcare industry with respect to both public and private health insurance and hospital operations. Dr Axel Baur has been supporting numerous pharmaceutical and medical companies in establishing global operating models, and developing strategies for private health insurance companies to exploit growth opportunities in Asia. He also has been guiding large transformations, both to extract synergies from acquisitions, and to substantively reduce operating costs and frequently advises pharmaceutical companies as they define their country-specific operational and “go-to-market” models. He invests much of his time to shape McKinsey’s thinking on how healthcare systems should address future challenges, which reflects his passion for innovative care delivery. Prior to joining McKinsey, Axel was an entrepreneur who launched a research-based biotech firm.

At Zimmer Biomet, we pursue possibilities.

It’s our promise to look beyond what’s possible now

and discover what’s possible next.

Every day, we focus on improving musculoskeletal healthcare.

It’s all we do. It’s all we have ever done.

We are committed to working by your side, and to break

through boundaries in pursuit of exceptional patient outcomes.

Visit us on the web at zimmerbiomet.com

©2016 Zimmer Biomet

It’s not just what we make...It’s what we make possible.

Corporate-Runner-Gold Sponsorship-2016 APAC MedTech Event.indd 1 10/28/16 9:31 AM

ASIA PACIFIC MEDTECH FORUM 2016 SPEAKERS BIOGRAPHY

26


Jaymie Claire Ang HenryFounding Executive Director, Global Alliance for Surgical, Obstetric, Trauma, and Anaesthesia Care (G4)

Dr. Jaymie Henry was the Founding Executive Director of the Global Alliance for Surgical, Obstetric, Trauma, and Anaesthesia Care (G4 Alliance). She holds an MD from the Philippines and an MPH from UC Berkeley School of Public Health.

Dr. Henry provided strategic direction to the G4 Alliance from its inception, developed and oversaw relations with stakeholders and partners, and organized political and advocacy events in support of surgical care at venues such as country offices, permanent missions, the UN, and the WHO.

Dr. Henry led the International Collaboration for Essential Surgery (ICES) where she led a campaign to raise the profile of Essential Surgery and hosted the first UN side event for Essential Surgery. She is the Executive Producer, director, and writer of the Global Surgery advocacy film, The Right to Heal, shown in over 60 countries worldwide and featured at the Lancet. She is one of the Bellagio Commissioners for the Lancet Commission on Global Surgery. Dr. Henry has spoken at the UK parliament, Johns Hopkins University, Muhammad Yunus Social Business conference (Bangladesh), and the World Congress of Surgical, Obstetric, Trauma, and Anaesthesia (Trinidad and Tobago).

She is currently completing her General Surgery residency at Florida Atlantic University.

Michel BirnbaumEntrepreneur-in-Residence, NTUitive

Michel is currently Entrepreneur in Residence at NTUitive, the innovation and enterprise company of Nanyang Technological University of Singapore, working on technology commercialization and spinoffs.

Michel’s career spans operational, advisory, finance and investments. He began his career as a Project Engineer at GE Military Engine Group. Michel has held senior investment banking roles in both European markets and NASDAQ, managing close to 30 tech and healthcare IPOs, follow-on debt/equity financings as well as merger and acquisition and private placement transactions. He has held both operational roles and board positions with a number of technology and healthcare companies. Michel’s most enjoyable projects include working on drug delivery development, advanced drone technology, deep learning neuro medtech and chronic disease solutions and being an investor in Unity 3D.

Formerly, a Partner at iGlobe Partners in Singapore, Michel has served as Vice Chairman of the Singapore Venture Capital Association (SVCA) and member of the Executive Council of BioSingapore. In 2013, Michel received the award for Highest Impact VC/PE backed Company Non-Executive Board member from SVCA. He remains an active startup tech/healthcare advisor in APAC and US.

Michel holds a B.Sc. in Aerospace Engineering from the NYU Tandon School of Engineering and attended General Electric’s Advanced Engineering program. Michel was an early graduate of General Electric’s Edison Program. He earned his MBA from London Business School.

His idea of a good time is spending time with his wife and three boys although they contributed significantly to his Vin Diesel look.

27


Dirk BiskupCo-Founder and Managing Director, Center for Genomics and Transcriptomics (CeGaT)

Dr. Dirk Biskup graduated from the University of Hamburg, Germany, and finished his PhD thesis on combinatorial optimization and complexity theory in 1999.Afterwards Dr. Dirk Biskup took different managerial positions within the industry.

In 2009 he co-founded CeGaT – Center for Genomics and Transcriptomics. CeGaT is the pioneer in applying NGS technology to diagnostic testing: large multigene Diagnostic Panels were invented by CeGaT in 2010. Today CeGaT has more than 120 employees.

In addition, Dr. Dirk Biskup co-founded three more biotech companies, which he also serves as managing director:

Cenata: Processing the Harmony Test in Germany – the worldwide first tech transfer of Ariosa/Roche. Today Cenata is the NIPT market leader in Germany.

CeMeT: Specialized on metagenomic analysis (16S and shotgun)..

CAG: Center for Animal Genetics, specialized on animal genetics and animal cancer therapy..

Supratim BoseExecutive Vice President and President, Asia-Pacific, Middle East & Africa, Boston Scientific

Supratim Bose is Executive Vice President and President, Asia-Pacific, Middle East & Africa (AMEA) for Boston Scientific, and a member of its Executive Committee. Supratim oversees the Company’s business across all countries in the AMEA region, including Japan.

Before joining Boston Scientific in January 2012, Supratim was Founder and Chief Executive Officer of Singapore-based Bose Consulting Group, which specialized in strategic management consulting services for the healthcare industry. Prior to that, he was with Johnson & Johnson for nearly 30 years, where he concluded his tenure as Company Group Chairman and member of its Global Operating Committee of its Medical Devices and Diagnostics business. He has been a member of the Board of CareFusion Inc., SMU Lee Kong Chian School of Business and Trireme Medical.

Anna Maria BraunPresident, Asia Pacific & Member of the Management Board, B. Braun Melsungen AG.

Anna Maria Braun is President, Asia Pacific and Member of the Management Board, B. Braun Melsungen AG. As President of Asia Pacific, she is responsible for the Group’s pharmaceutical and medical technology business in the entire region. Based in the Regional Headquarters in Penang, Malaysia, Ms. Braun also oversees one of the Group’s largest production sites. Ms. Braun is a qualified Attorney-at Law with a degree in Law from the University of Freiburg, Germany and a Masters in Law from Georgetown University in Washington, DC. She has been admitted to the Bar in Germany and in New York State, USA. Anna Maria Braun is married and has two children.

28


Chris ColwellSenior Director, Public Affairs, Greater Asia, Becton Dickinson (BD)

Mr Chris Colwell is Senior Director, Public Affairs, Greater Asia at BD, where he is responsible for leading the company’s public policy and public affairs strategies in the Asia Pacific region.

Prior to joining BD, Mr Colwell served as the Director of Vaccines and Diagnostics Policy at the Biotechnology Industry Organization (BIO). While there, he directed policy and advocacy issues related to vaccines, pandemics and emerging diseases, diagnostics, and personalised medicine. Mr Colwell’s previous work includes the U.S. Food and Drug Admministration’s Office of the Commissioner in the Office of Counterterrorism and Emerging Threats Policy, where he worked on policies related to the development and approval of medical countermeasures. He was a fellow with former U.S. Congressman James Greenwood, developing internet pharmacy regulation, and also worked in the pharmaceutical industry synthesising health economics studies.

Before focusing his career on policy matters, Mr Colwell worked in the vaccine division of Merck and Co. Inc., where his final position was Area Head of Bacterial Vaccine Manufacturing. His responsibilities at Merck included vaccine facility design, construction and validation; process scale-up; and management of on-going manufacturing processes, including regulatory affairs.

Mr Colwell received his Master in Public Policy from Georgetown University and a Bachelor of Science in chemical engineering from the Pennsylvania State University.

Jose Calle CordoCEO, Biosensors International Group

Mr Jose Calle Gordo joined Biosensors in 2014 as CEO. In October 2016, he has been appointed Vice Chairman of the Board.

He had a successful career of over 25 years in the medical device industry having served in various vice president and managerial roles at Abbott, Guidant and Eli Lilly. At Guidant, he led the development and commercialisation of Xience, a family of drug eluting stents (DES) and market leader for the treatment of coronary artery disease.

At Abbott, he managed the international operations outside of the US and led the commercial introduction of the first bioresorbable vascular scaffold (ABSORB BVS) and the first percutaneous treatment for mitral valve repair (MitraClip)

Previously at Guidant and Eli Lilly, he contributed to the commercial and therapy development of the implanted defibrillator (AICD) and cardiac resynchronization therapy (CRT).

He received his Electrical Engineering degree from Universidad Politecnica de Madrid, Spain.

Hunter CherwekMedical Director- Strategic Markets, Alcon Laboratories

Hunter Cherwek, MD, is an ophthalmologist working at Alcon Laboratories as the Medical Director- Strategic Markets based in Beijing, China, since 2011. He received his medical degree at Duke University and graduate medical training at Scripps Hospital & Emory University.

Prior to joining Alcon, he worked for 6 years as an ophthalmologist and Medical Director at ORBIS International, a blindness prevention NGO, on the Flying Eye Hospital, long term country programs, and telemedicine/distance learning initiatives.

He has now worked in over 22 countries and has specific career interests in preventable and treatable causes of blindness in low resource settings

29


Pavan ChoudaryDG & Chairman Medical Technology Association of India (MTaI)

Pavan Choudary, is the Managing Director of Vygon India a leading French Multinational in the field of Healthcare. He is also an active member on the world-wide strategy planning effort and spearheads its M&A initiative in India. He has earlier held important positions in Marketing & Strategy at Dabur, Cadila, Lintas among others.

He is the author of The Rx Factor, a seminal work on healthcare marketing and strategy. His other path breaking book, How a Good Person can Really Win (revised edition of When you are Sinking Become a Submarine) has won the Eric Hoffer Award and Readers’ Choice Awardin 2015. He has co-authored the Hygiene guide, Broom & Groom with Kiran Bedi and Lal Bahadur Shastri: Lessons in Leadership with Congressman Anil Shastri. He hosts the nation building TV show Hum Aisey Kyun Hain on DD (where he raises social reform, civic & healthcare issues), writes the column Mera Gaon Mera Desh for the Times of India, and has served as Editor of the magazine, Pharma Trendz Today. The Times of India once rated him, “amongst the foremost thinkers of the world”.

A highly regarded Management Strategist, Pavan coaches leaders on life & management skills and sits on the advisory boards of some of the most respectable organizations of India. He is often consulted by the managements of hospitals to help them improve their revenues, bottom line & environments.

Pavan has been awarded with the Global Leadership Award by the Bhartiya Vidyapeeth University.

Mahbubur ChowdhuryChairman, Bangladesh Eye Hospital

Dr. Mahbubur Rahman Chowdhury completed his MBBS from Dhaka Medical College. He obtained his Fellowship in Ophthalmology in the year 1991. He has done post-graduate fellowship in Phaco Surgery at Rahgudeep Eye Clinic, Ahmadabad and LV Prasad Eye Institute, Hyderabad, India. He has introduced Phaco Surgery in Bangladesh. He is a high volume Phaco Surgeon, doing more than 1000 surgeries every year.

Bangladesh Eye Hospital was established by him in 2004, the first sub-specialty based eye hospital in Bangladesh which has now five branches in Dhaka and Chittagong.

He founded Bangladesh Eye Trust Hospital, a non-profit eye hospital for the underprivileged.

Dr. Chowdhury has started the post-graduate fellowship programs for ophthalmologists at Bangladesh Eye Hospital and total 22 ophthalmologists have completed fellowship in phaco surgery till date. Recently fellowship in Glaucoma, Retina and Uveitis has also been introduced.

He also established a charitable eye hospital, Abdul Hai Chowdhury Eye Hospital and Sufia Chowdhury High School in his village at Narsingdi.

Dr. Chowdhury has also taken initiative to take the health services in Bangladesh at international standard, by establishing Bangladesh Specialized Hospital. A multi-disciplinary hospital in Dhaka. He has several publication and presentation to his credit at national and international forum.

30


Raymond ChuaGroup Director, Health Science Authority (HSA)

Asst Prof Raymond Chua began his medical career after graduating from the Faculty of Medicine in National University of Singapore in 1997. He became certified as a Registered Public Health specialist and Fellow with the Academy of Medicine, Singapore in 2007. He was awarded a scholarship by the Ministry of Health to take up a Masters of Science in Public Health with the London School of Hygiene and Tropical Medicine, University of London, in 2002.

In 2007, he left the public service to join Eisai Co Ltd in June 2007 as the Managing Director of Eisai Clinical Research Singapore. In 2010, he joined Shire Pharmaceuticals as their International Medical Director to oversee the growth and development of Shire’s products in Asia-Pacific. In July 2011, Asst Prof Chua joined Health Sciences Authority (HSA) and was designated as the Group Director of the Health Products Regulation Group (HPRG) since May 2012 to provide oversight of the regulations of all health products in Singapore.

Campbell ClarkChief Ethics & Compliance Officer, Asia Pacific, Medtronic

Campbell Clark is Chief Ethics & Compliance Officer, Asia Pacific, for Medtronic, a medical devices company, and is based in Singapore. He was previously General Counsel, Asia, for Covidien, another medical devices company. Covidien was acquired by Medtronic in January 2015, and he now engaged in legal and compliance integration activities in Asia Pacific for Medtronic. Prior to joiningCovidien in 2008, Campbell was the Assistant General Counsel, Australia and New Zealand, for Tyco International. He has also held senior roles in-house as an international legal counsel in Japan, and in private practice as a litigation lawyer in New Zealand and the United Kingdom.

Mr Clark graduated from the University of Auckland, New Zealand, and holds an LL.B (Hons) and M.Jur (Dist.).

Zubin DaruwallaDirector, PricewaterhouseCoopers (PWC) South East Asia consulting

Dr. Zubin J Daruwalla is a Director in PwC South East Asia Consulting and leads the healthcare team in the region, while remaining a practicing clinician with an interest in orthopaedics.

With almost 20 years of experience in health, prior to working at PwC, Zubin’s career in healthcare provision from a surgeon’s standpoint has included working in both the public and private sectors across continents, including cities like Dublin, Oxford and Singapore. This has allowed him to gain experiences globally that help provide his clients insights that assist in solving their most complex challenges.

Zubin has extensive experience in Digital Health, Medical Education, HealthTech and MedTech, and is a Consultant, Advisor and Mentor to a number of start-ups and individuals in these spaces both locally as well as internationally.

Dr Rana DasguptaChief Operating Officer, Apollo Hospitals Group

31


Martin DewhurstDirector and Senior Partner, McKinsey’s London office

Martin is a Director (Senior Partner) in McKinsey’s London office and has extensive global experience across US, Europe and Asia. He joined McKinsey in 1992.

Martin leads our Global Pharmaceutical and Medical Products Practice (PMP). He is responsible for our overall client service agenda, our knowledge and research priorities, our offerings to clients and the development of our people.

He is currently leading a major McKinsey initiative on “Biopharma frontiers” looking at the key trends shaping the industry. He has also spoken widely including at the Financial Times conference, Biobusiness, EUCOMED and St Petersburg economic forum, among others.

He has written and spoken frequently on globalisation. He has published in the Harvard Business Review (2013) and led a panel on emerging markets at the Economist conference.

Matt DurackSenior Design Director, Lunar Design Singapore

Matt is a Senior Design Director co-leading the new LUNAR hub in Singapore delivering design to McKinsey’s clients in Asia. He has over 20 years of product design experience, with deep expertise in turning science and medical technologies into products. He has a unique combination of design & engineering skills, life science training, multidisciplinary team leadership and client management. He has worked on >30 award winning products for Fortune 500 & startup companies including: Illumina, Abbott Laboratories, Becton Dickinson & Company, Optimedica, Varian Medical, Abbvie, Gen-Probe, Bio-Rad & Medtronic.

Claudia Süssmuth DyckerhoffSenior External Advisor, McKinsey

Claudia Süssmuth-Dyckerhoff is a Senior External Advisor to McKinsey as of March 1st 2016, and till then was a Senior Partner/Director at McKinsey & Company. In March and April 2016 she was elected to join the Board of Directors of Roche and the Board of Directors of Clariant. She joined McKinsey & Company in 1995 in Switzerland. Since then she has focused on working for Healthcare companies - pharmaceutical/medical device companies, payor, provider and health systems in Europe, the US and since January 2006 in Greater China and across Asia. In 1998 she joined the New Jersey Office for a 15-month period. In addition to her leadership role in the Pharma/Health Care Practice in China and Asia, Claudia lead our Asia Health Systems and Services Sector in Asia.Most of her work has been focused on market entry or market growth strategies across TAs as well as for medical device players, business development across Asia, assessment of potential privatization assets in the health services arena, commercial excellence, organizational redesign and capability building.

Claudia Süssmuth Dyckerhoff holds a PhD in Business Administration from the University of St. Gallen/University of Michigan Ann Arbor focusing on strategy and organization (1995) and she holds an MBA from ESADE in Barcelona (1992).

Before studying Business Administration she was trained as a banker at Deutsche Bank AG in Germany.

Claudia is married and mother of four boys and one girl.

32


Michael EtterChief Medical Officer and Senior Vice President Medical Affairs, Fresenius Medical Care Asia Pacific

Michael has joined Fresenius Medical Care in 2009 and is responsible for all medical aspects related to the medical device and pharmaceutical business segment of FMC as well as for the health care services provided by FMC in the Asia Pacific region comprising more than 400 medical institutions. He graduated from the Technical University Munich Medical School (Germany) and holds board certifications in surgery and emergency medicine. He subsequently completed his Master’s degrees in Business Administration as well as in Public Health.

Russell L. GruenVice-Dean (Research) & Professor of Surgery, Lee Kong Chian School of Medicine (NTU)

Prof Russell Gruen is Director of the Nanyang Institute of Technology in Health and Medicine (NITHM) at Nanyang Technological University, and Vice-Dean (Research) and Professor of Surgery in the Lee Kong Chian School of Medicine, and a Consultant General Surgeon at Tan Tock Seng Hospital in Singapore.

Prof Gruen is expert in health systems of many types and at many levels, ranging from molecular processes and functional anatomy through to the organisation and delivery of health services. Before moving to Singapore Prof Gruen was Director of the Australian National Trauma Research Institute, during which he established significant national and international collaborations, including the Australian national trauma registry, and the Australia-India Trauma System Collaboration. His research interests span innovations for injury prevention, the control of bleeding, management of traumatic brain injury, and how trauma systems are best organised to provide time-critical care and promote long-term recovery. Through establishment of the WHO Global Alliance for Care of the Injured, and as a Lancet Commissioner in Global Surgery, he has led worldwide healthcare improvement efforts.

His work is by its nature interdisciplinary, bringing together ideas and expertise from diverse fields such as medicine, engineering, philosophy, and economics. It is also highly translational, with strong emphasis on what works best for the benefit of patients. In addition to his Australian medical degree, specialist surgical qualifications and a PhD in health systems research, Gruen has postdoctorate qualifications in health policy, medical ethics and business management from Harvard. He has over 160 publications spanning observational studies, clinical trials, systematic reviews and health policy articles, and many in leading journals such as The Lancet, JAMA and New England Journal of Medicine. He has received Australia’s premier clinician scientist awards, including the Practitioner Fellowship of the Australian National Health and Medical Research Council, and the John Mitchell Crouch Fellowship of the Royal Australasian College of Surgeons.

As Director of NITHM, Prof Gruen drives interdisciplinary research at NTU, connecting with engineers and healthcare providers to solve major global health challenges.

Richard HamiltonChief Legal Counsel, International Stryker Corporation

Rich is currently Chief Legal Counsel, International for Stryker Corporation with responsibility for Legal and Compliance services in all geographies outside of the United States and Western Europe. Since 2014, he has worked out of the Stryker Headquarters in Singapore. Rich joined Stryker in February 2011 as a member of the Stryker Orthopaedics Group Legal team, and became Senior Legal Counsel, Reconstructive Division and Senior Director, Orthopeadics Group Compliance in April 2013. Prior to joining Stryker, Rich was a partner with the New Jersey law firm of Stern & Kilcullen, where, among others, he served as counsel to the Federal Monitor for UMDNJ, and as outside counsel to Stryker Orthopaedics where he helped to successfully guide the company through the Non-Prosecution Agreement and federal monitorship period from 2007-2009. His legal background is focused on fraud and abuse, ant-corruption issues, corporate investigations, and litigation. Rich received his Juris Doctorate from Rutgers University and his B.A. from Rutgers College.

33


Gladdy HeSenior Client Partner, Korn Ferry’s Shanghai office

Gladdy He is the Senior Client Partner in the Shanghai and Singapore offices of Korn Ferry. She is a member of the Global Life Sciences Market and leading the Medtech Practice in APAC region. Ms. He has more than two decades of work and life exposure across US, China, Southeast Asia, and Europe. She possesses extensive global HR consulting experience, including executive search, executive coaching, succession management, leadership development. She holds a MBA degree from Wharton Business School and serves as board member on a number of NGO and charitable organizations.

Jake HenryManaging Partner, McKinsey’s Chicago office

Jake Henry is the managing partner of McKinsey’s Chicago office. He is a core leader of McKinsey’s Medical Products practice and serves a range of companies across the sector spanning therapeutic implantables, capital equipment, consumables and supplies. Since joining the Firm in 2000, he has served numerous medical product and pharmaceutical companies, with a focus on corporate strategy, risk management, M&A, commercialization strategy and launch effectiveness, and BRICIT market entry. Prior to joining the Firm, Jake obtained a B.S.E. in mechanical and biomedical engineering from Duke University. He then completed his Ph.D. at Duke University in mechanical engineering, developing expertise in control systems, aerodynamics, acoustics, and vibrations. Jake is also an active leader in many Chicago civic enterprises. He serves on the boards of both the Civic Consulting Alliance and Choose Chicago, a destination marketing organization. He is also an active volunteer for the Chicago chapter of Pets Are Worth Saving (PAWS).

Patrick HoltPresident of Medical Products, Cardinal Health Asia Pacific

Patrick Holt is the president of Cardinal Health Medical Products in Asia Pacific. He also serves as the regional leader of Cordis, a Cardinal Health company. Cordis is a worldwide leader in the development and manufacture of interventional vascular technology with more than 50-year history of delivering pioneering products to treat millions of patients. Cardinal Health helps pharmacies, hospitals and ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality.

With 18 years of experience in the healthcare industry, Patrick brings to Cordis and Cardinal Health agile leadership skills, strong industry knowledge and deep experience across key Asia Pacific markets. Patrick has led organizations through start-up, turnaround, joint ventures, mergers and acquisitions and organizational transformations.

Before joining Cardinal Health, Patrick served at Allergan in various leadership positions. He held the roles of Asia vice president and regional managing director and was responsible for leading Allergan’s business across the region. Prior to that, he served as vice president and managing director for key markets including Greater China, Japan and Korea. Patrick’s early career was with MSD, where he spent over 12 years holding a series of leadership roles in Australia, Korea and Indonesia.

Having served in commercial and product development roles, Patrick brings strong expertise in end-to-end commercialization in key therapeutic areas including cardiovascular, endocrinology, ophthalmology, neurology, urology, osteoporosis, pain and medical aesthetics within medical devices and pharmaceuticals.

Patrick holds a bachelor’s degree in in biochemistry and chemistry from Monash University, Australia. .

34


Choongman HongDirector, Department of Medical Device Evaluation, Ministry Of Food And Drug Safety Korea

Choongman Hong, became the Director of orthopedic and restorative device division at Korea Ministry of Food and Drug Safety (MFDS) in November 2015.

He previously served as Director of Medical Device Safety Management Division in the regional office of MFDS, beginning in May 2013.

He have been working for Korea MFDS about 7 years to assure the safety, effectiveness, and quality of medical devices and to foster device innovation.

Hereceived my M.S. and Ph. D degrees majored in Toxicology from Seoul National University in Department of Veterinary Medicine. He have been holding various medical device evaluation and research positions within MFDS from 2009 to present, and am currently serving in leadership roles at Korean Society of Toxicology as a chairman and at Korean Society of Medical and Biological Engineering as a Board of Director member.

Bassam JabryManaging Director, Chemistry

Bassam is Chemistry’s Managing Director, consulting on user-centred experience design.

He has had the fortune of working with some of the biggest brands in the world, starting his career as a Product Designer at Philips Electronics for 5 years before joining Chemistry in 2002.

Since then he has grown the agency from a classic product and graphic design studio, to today as a research based, experience design consultancy, working across diverse industry sectors to help organisations like Dell, Singapore Tourism Board and GE Healthcare to solve complex challenges and win design awards.

His work is also featured at the Singapore Art Museum and his opinions and ideas have been covered on Channel News Asia, and the Singapore Business Times newspaper.

Bassam was born in the UK and holds a 1st Class BSc (Hons) in Product Design from Brunel University, UK.

Elesh Kumar JainConsultant, Public Health, Hospital Administrator and Consultant, Paediatric Ophthalmology, India

An aspiring ophthalmologist who have a deep passion in making quality eye care available for all. For the last eight years he has been handling various key roles at Sadguru Netra Chikitsalaya. Sadguru Netra Chikitsalaya is a state-of-the-art Tertiary Eye care Hospital situated in the rural part of central India Chitrakoot, He has specialized in pediatric eye care He has been performed more than 18000 Cataract, squint and other surgeries. As a senior professor Ophthalmology, he also guides the academic and research activities .Dr.Elesh Jain ,apart from his regular practice at Department of pediatric ophthalmology and strabismums, heads the public eye health initiative at Sadguru Netra Chikitsalaya.

35


Yoshitaa JayabalanPatient speaker

Yoshitaa Jayabalan, 23 year old, currently a final year medical student in Malaysia. I was diagnosed with type 1 Diabetes mellitus 10 years ago, at the age of 13. Due to the lack of awareness on Type 1 diabetes, I was very much restricted from having a “normal” life as a teenager. I faced judgements and criticism from others who did not know the disease well. My aim as a medical student and a future doctor is to bring awareness to this invisible disease as well as to prove to patients with type 1 diabetes that living a normal life is possible with balance.

Robert K. KameiAssociate Provost (Education) and Director, Institute for Application of Learning Science and Educational Technology (ALSET), National University of Singapore (NUS)

Professor Robert Kamei is Associate Provost and Director, Institute for Application of Learning Science and Educational Technology at the National University of Singapore.

In 2006, he served as the Vice Dean, Education at Duke-NUS Medical School, importing the curriculum from Duke University and transforming it through a new pedagogy called TeamLEAD which subsequently influenced curriculum development at Duke University and educational institutions across Singapore and internationally.

Professor Kamei holds a degree in Human Biology from Stanford University and a medical degree from the University of California, San Francisco. He was the Director of Residency Training at UCSF for 16 years.

Professor Kamei co-edited the textbook, “Fundamentals of Pediatrics” with Dr Abraham Rudolph which became one of the most popular references on Paediatrics.

Putty KartikaCountry Director, Medtronic Indonesia

Country Director of Medtronic Indonesia, has joined company in April 2015 and started the legal entity establishment managing Cardiovascular, Minimally Invasive Technologies for Surgical, Restorative Therapies and Diabetes Business in Indonesia for the first year Legal entity development.

Putty brings with her 27 year’s rich experiences in Healthcare, and Lifesciences Industries as well as Consumer market. Prior to join Medtronic, Putty worked for BBraun Medical German Company as aVice President Director for Indonesia where She was responsible for all Commercial part in BBraun Indonesia.

Earlier, Putty was the General Manager with BSN German Company for develop Wound Management and orthopedic product. Before that, She was the Marketing Manager for Beiersdorf German Company. Ibu Putty holds and a Master in Pharmacist from the Institute Technology Bandung. She is based in Jakarta, Indonesia.

36


Sherry KeramidasFounder and CEO MindfuLeadership

Dr. Sherry Keramidas has dedicated her professional career to driving innovation, effective strategy and responsive policy in the global biomedical and health arenas by guiding leaders and organizations to examine issues and consider solutions in new ways. Her career includes over 25 years as CEO of international health professional organizations and nearly 10 years in senior management roles with organizations including the National Institutes of Health and the Cystic Fibrosis Foundation. Her experience spans work in all continents and with government, non-profit, academic and for profit organizations.

For 20 years, Dr. Keramidas served as the Executive Director of the Regulatory Affairs Professionals Society (RAPS). During her tenure, RAPS became the leading global organization dedicated to the health product regulatory profession with members in more than 65 countries. She guided RAPS to expand the only post-academic professional credential and to establish highly acclaimed professional education and training programs. Her efforts helped RAPS to establish collaborative initiatives government agencies, NGOs, academic and research organizations and corporations around the world.

In 2016, Dr. Keramidas created MindfuLeadership, bringing her first-hand experience and personal skills to develop innovative and effective leaders and organizations. Combining a background in scientific research and management, Dr. Keramidas helps executives and organizations to develop vision, strategy and execution; effective multi-generational and empowered staff; strong board/staff partnerships; and approaches for working in a global environment.

Previously, Dr. Keramidas served as CEO of the American College of Dentists, as the Associate Executive Vice President of Research and Education of the American Physical Therapy Association, and as the Scientific Director of the Cystic Fibrosis Foundation. She also served as a special consultant to the National Institutes of Health working on research program evaluation, strategic planning and interagency collaboration in the Office of the Director and across all NIH Institutes and Centers.

Dr. Keramidas received her PhD in neurosciences and physiological psychology from Pursue University. She participated in executive education programs at the Kellogg School of Management and Haas School of Management. She is a Fellow of the American Society of Association Executives and holds the Certified Association Executive designation. She is also a certified executive and leadership coach. Dr. Keramidas served on the boards of several nonprofit and academic organizations.

37


Haresh KhoobchandaniGeneral Manager, Microsoft Business solution APAC

Haresh Khoobchandani is the general manager of Microsoft Business Solutions for Asia Pacific, based in Singapore. With more than 20 years of experience at Microsoft, Haresh brings unique depth and breadth of regional expertise across both Sales and Marketing disciplines to drive expansion in Asia Pacific.

Previously, Haresh was the managing director of Microsoft Thailand, where he led its transformation from a primarily on-premise software business to a mobile-first cloud-first company, while simultaneously guiding customers and partners in their own cloud transformation. Deeply engaged with Microsoft’s educational initiatives in Thailand, he led the provision of free Office 365 access to 8 million Thai students through Microsoft’s largest-ever cloud education partnership with the Office of the Basic Education Commission (OBEC).

Since joining Microsoft in 1997, Haresh has held various leadership positions in driving both operational and marketing excellence. This includes serving as chief operating officer at Microsoft Indonesia, where he oversaw over 30 percent growth in the subsidiary.

Haresh has also held leadership positions in Microsoft’s Singapore and Malaysia operations as well as the company’s Asia Pacific Regional Headquarters in Singapore. This includes serving as chief marketing officer for the Consumer & Online business in Asia Pacific he focused on driving thought leadership, brand preference and marketing effectiveness. During his tenure he increased marketing efficiency, led the introduction of digital into the marketing mix and transformed the marketing function to deliver consistent growth across the business.

At Microsoft Singapore, he was responsible for overall business operations and marketing strategy, At Microsoft Malaysia, Haresh served as Senior Director for Asia Pacific’s small and mid-market business group and led the small and medium customer segment business, where he successfully grew the business by 45 percent over two years.

Prior to joining Microsoft, Haresh was the business development manager at Tech Pacific Singapore Pte Ltd, a distribution company, where he more than tripled profit margins in the consumer business. He developed the business model for IT retail in non-traditional IT commercial settings, as well as worked with Courts Singapore to integrate their computer retail business into their consumer electronics and furniture business.

Haresh is a distinguished public speaker and commentator, with engagements including “Redefining Education in the 21st Century” at TEDxChiang Mai, the Bloomberg ASEAN Business Summit in Bangkok, the Harvard College in Asia Program, and the Bloomberg special “Thailand: Inspiring Opportunities”.

In recognition of his thought leadership in marketing he was awarded the Global Brand Leadership Award at the World Brand Congress 2011.

Haresh is a certified coach, counseling senior executives on achieving personal and organizational growth, transformation and success in the digital age. He holds a Masters of Business Administration with Distinction from the University of Stirling, and is a graduate of the executive course in Leading Change and Organizational Renewal at Harvard Business School. Outside of work, Haresh and his wife enjoy spending time with their two children.

38


Jun KitaharaDirector, Division of Regulatory Cooperation, Office of International Programs, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Dr. Jun KITAHARA has been a Director, Division of Regulatory Cooperation, Office of International Programs at the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, responsible for International coordination between PMDA and other regulatory agencies, since April 2012.

Prior to his current position, he served as the Review Director within Office of medical device II, responsible for reviewing orthopedic product from July 2010 through March 2012. His work experience in PMDA including Manager of IT, Review management and New drug reviewer.

Dr. Kitahara spend half year at US FDA as visiting reviewer from PMDA in 2006 and 1 year at Swissmedic as a liaison between Swissmedic and PMDA in 2014 to 2015.

Amar KureishiHead, Clinical & Regulatory Affairs for Region Asia/Russia

Dr. Amar Kureishi is currently the Regional Head of Clinical & Regulatory Affairs for Asia/Russia for Alcon, a Novartis division. In his current capacity, Amar is responsible for the clinical development, regulatory approval, and medical oversight of all Alcon products for Asia and Russia. Alcon is the world’s leader in eye-care, providing innovative solutions for such vision-threatening diseases as cataract, glaucoma and refractive errors.

Amar is a physician, and a specialist in internal medicine and infectious diseases. He obtained his medical degree from the University of Alberta, in Edmonton Canada, and his postgraduate medical training in Calgary and Vancouver. He started his career in academia and was Associate Professor at the University of Calgary, Canada, and a consultant physician at Foothills Hospital, Calgary.

He joined Bayer Healthcare in 1999, and in his eleven years with Bayer held successively senior R&D positions, including head of Clinical Development & Medical Affairs for Asia, and Global Head of Medical Affairs. In 2010 Amar joined Quintiles as the Regional Chief Medical Officer and Head of Drug Development for Asia, a position he held until 2015 before moving to his current position with Alcon.

During his career, Amar has had international posting in the US, Germany, China and Singapore. He is a Fellow of the Royal College of Physicians and Surgeons of Canada, and an alumnus of INSEAD, and has authored over 60 scientific papers and abstracts.

Benjamin KwakVice President, Compliance Officer & Senior Legal Counsel, Asia Pacific, Zimmer Biomet

Benjamin Kwak is the Vice President, Compliance Officer and Senior Legal Counsel, Asia Pacific, for Zimmer Biomet, a U.S. medical device company. Prior to joining Zimmer Biomet, Mr. Kwak was in private practice in Washington, D.C., where he focused on white collar criminal defense, government investigations, and corporate compliance matters. He represented multinational corporations in matters involving the Foreign Corrupt Practices Act, and has conducted internal investigations and anti-corruption compliance reviews throughout Asia, Europe, and Latin America. Mr. Kwak received his B.A. in Public and International Affairs from Princeton University and his J.D. from Columbia Law School.

39


Lok Mun Leng Deputy Director, Group Procurement Office, SingHealth

Mun Leng has more than 17 years of experience in managing supply chain and he has helped to play a key role in transforming the supply chain management to a proactive model in SingHealth Group. His previous role includes assisting the Group Chief Procurement Officer in developing strategic plan for supply chain management in non-pharmaceutical area.

He currently leads the team that manages clinical and non-clinical supplies & equipment, IT and major contract services with an annual spend of SGD 300 million. He also partners with the Agency for Integrated Care to help more than 25 nursing homes in aggregate buy.

Prior to joining SingHealth, he manages the purchasing team of the Singapore General Hospital (SGH) and in operations support role such as Security Manager in SGH. In 1999, he also serves in the SGH Education & Training Department to facilitate the skills redevelopment programme for the healthcare industry.

Mun Leng was a former Senior Police Officer with the Singapore Police Force and has hold appointments in investigation, command and staff functions.

John CW LimDeputy Director of Medical Services (Industry & Research Matters), Ministry of Health, SingaporeExecutive Director, Centre of Regulatory Excellence, Duke-NUS Graduate Medical School, Singapore,Chairman, Singapore Clinical Research Institute

Dr. John Lim is a medical graduate of the National University of Singapore (NUS), with Masters degrees in Public Health from NUS and Health Policy and Management from Harvard University. He has held senior Ministry positions in Health and Education.

Dr. Lim was Chief Executive Officer of the Health Sciences Authority from 2006-2014.

He is concurrently Deputy Director of Medical Services (Industry & Research Matters) in MOH and Executive Director, Centre of Regulatory Excellence (CoRE) at Duke-NUS Medical School. The MOH role is equivalent to a deputy chief medical officer coordinating research policy and industry engagement. In CoRE, Dr. Lim draws on his international experience and networks to enhance health products regulatory capacity and scientific excellence in Asia-Pacific.

Dr Lim is Chairman of the Singapore Clinical Research Institute, a national Academic Research Organisation, and a member of the Executive Board of the APEC Life Sciences Innovation Forum.

40


James LimExecutive Vice President and President, Great Asia of Becton Dickinson (BD)

Mr. James Lim, Executive Vice President and President, Greater Asia of BectonDickinson or BD is currently the first Asian on the BD’s Senior LeadershipManagement Committee reporting to the CEO. A leading Global Medical technology company BD develops manufactures and sells medical devices, instrument systems and reagents. The company headquartered in Franklin Lakes, New Jersey, employs nearly 30,000 associates in more than 50 countries throughout the world.

James joined Becton Dickinson in 1994 from Seagate International, as Engineering and Facility Manager of BD Medical (Singapore), and after a 3-year assignment in R&D, he became Plant Manager in year 2000. In 2003, he was promoted as Director of Operations, Asia Pacific, where he was responsible for the regional Manufacturing organizations and Supply Chain function, covering plants from Bawal in India to Suzhou in China. In April 2008, he was appointed as Vice President for Central and Asia Pacific responsible for Central Asia Business Management and the overall support functions for entire Asia Pacific region.

Four years later he was appointed as President of Greater Asia and an Executive member of the Company. Mr. James Lim leads Greater Asia that covers China, Japan, Taiwan/HK, Australia, and New Zealand, Korea, SEA, India and Pakistan. James had his earlier education in Malaysia but studied at the National University of Singapore where he graduated with a Mechanical Engineering Degree. James occasionally participates as a panel member at regional Business Leader’s meetings to learn more from others and sharing different views on how to tackle business issues. James was awarded the Leading CEO in July, 2014 by the Singapore Human Resources Institute (SHRI) for his “dedication, championship of innovative and effective HR ideas and practices, and demonstration of leadership in the industry.”

James is married with two teenage sons. He is passionate about automotive and sports.

Jeremy LimPartner, Head of Health & Life Sciences, Asia Pacific, Oliver Wyman

Dr. Jeremy Lim is a Partner in Oliver Wyman’s Singapore office, where he leads our Health and Life Sciences practice across the Asia Pacific region • Jeremy has extensive experience consulting and advising multi-national clients on national and regional strategies for market positioning and expansion including acquisitions as well as sense-making of various healthcare reforms regionally. Jeremy also holds diverse senior level executive roles in the Singapore public and private sectors.

Dr. Lim is active in academia, holding appointments in a number of universities. He teaches a popular graduate course in the National University of Singapore on “Managing Health Services Organizations ”

He writes regularly for both the scientific and popular media and last year authored “Myth or Magic: The Singapore Healthcare System”, a book on the Singapore health system and the lessons for health reform efforts in other countries

Prior to joining Oliver Wyman Jeremy worked in senior executive roles in both public and private sectors. He also spent time in the Ministry of Health Singapore as a senior official.

Dr. Lim chairs the steering committee of NIHA (NUS Initiative to Improve Health in Asia), an initiative to strengthen health policy research and education in Asia, is a Member of the International Advisory Board, Health Authority Abu Dhabi and sits on the Advisory Council Behavioural Sciences Institute, Singapore Management University. He also contributes as President of the Fulbright Association (Singapore) and convener for the Johns Hopkins Bloomberg School of Public Health Singapore alumni

A medical doctor by training, Jeremy holds a master in public health degree from the Johns Hopkins School of Public Health and a master in medicine (Surgery) from the National University of Singapore

41


Ronald LingCo-founder, Galen Growth Asia

Dr Ling is co-Founder and Director of Galen Growth Asia, an independent organisation which aims to catalyse the development of Asia’s HealthTech ecosystem by fostering collaboration between startups, investors, corporations, government and other stakeholders.

He is also Founder and Managing Director of Sanus Advisory Asia, an independent healthcare advisory firm in Singapore.

Prior to setting up Sanus Asia, Dr Ling was Managing Director of Pricewaterhouse Cooper’s Healthcare practice and the firm’s Asia Healthcare Leader. He was also previously a partner with Symphony Asia (formerly Schroder Capital Partners); a mid-sized private equity firm based in Singapore.

Prior experience also includes 5 years as a consultant with McKinsey & Co, London where he focused on work with pharmaceutical clients.

Dr Ling holds an MA (Oxford), MBBS (London) and MBA (INSEAD).

Wiliam P. MageeCEO and Co-Founder, Operation Smile

Dr. William P. Magee, Jr. is the CEO and Co-Founder of Operation Smile, an international medical charity with a presence in more than 60 countries, whose network of more than 13,000 medical volunteers from over 80 countries is dedicated to helping improve the health and lives of children.As a leading plastic and craniofacial surgeon, Dr. Magee has trained thousands of physicians worldwide, holds honorary doctorates from many prominent global universities, and authored and co-authored scores of articles in professional journals. A sought-after speaker, he has delivered keynote speeches for some of the largest international corporations in the world, given numerous commencement addresses, and has appeared in national publications, documentaries, television series and international news programs.

Under Dr. Magee’s leadership, Operation Smile has provided more than a quarter of a million free surgeries for children and young adults born with cleft lips, cleft palates, and other facial deformities since 1982.

Vladimir MakatsariaAPACMed Chairman, Company Group ChairmanJohnson & Johnson, Asia Pacific

Vladimir Makatsaria is Company Group Chairman, leading the Medical Devices Group in Asia Pacific. Additionally, he serves as the Chairman of Johnson & Johnson China, with enterprise-wide responsibilities.

Vladimir began his career with Johnson & Johnson as a sales representative in Russia in 1996. He went on to hold several general management positions of increasing responsibility, including Managing Director in Russia, Area Director in Eastern Europe, President in Europe Middle East & Africa.

Vladimir is the Chairman of the Asia Pacific MedTech Association and a member of the Business Advisory Board of the Singapore Management University.

Vladimir holds a Bachelor’s degree in Physiology and Master’s degrees in Healthcare Administration and Business Administration from the University of Minnesota.

42


Koji NakaoCorporate Adviser And Former Chairman, Terumo Corporation

Mr. Nakao was the chairman of Terumo Corporation for five years and retired as of June, 2016. He is currently a corporate advisor.

His job responsibilities with Terumo included sales & marketing, corporate strategy planning, and M&A besides being the head of the subsidiaries and the operations in the United States. He has been serving as chairman at JFMDA for 4 years and are engaging in various activities for the medical device industries, while being appointed to the member of Japan/US Business Conference, Japan/EU Round Table and the various government committees.

Hareesh NairDirector, Quadria Capital

Hareesh is a Director of Quadria Capital, among Asia’s largest private equityinvestors dedicated to making investments into healthcare businesses in the region. He has over 14 years of global transactional, strategy, and operationalexperience within the healthcare industry, and participates within the Board of Commissioners of SOHO Group, one of Indonesia’s leading healthcarecorporations, as Chairman of both the Nomination and Remuneration, and Audit Committees.

Prior to Quadria, Hareesh was a senior member of Medtronic’s BusinessDevelopment and Strategy team in Singapore, and formerly a Principal withinMedtronic’s Minneapolis-based Corporate Development team, where he completed 11 significant investments encompassing over US$500M. Hareesh has prior experience with Gilead Sciences and Becton Dickinson in various sales finance, operations, & engineering leadership roles.Hareesh also serves as an Advisory Board Member for Singapore-MIT Alliance for Research and Technology (SMART). Hareesh completed an MBA from Wharton as an H.O. West Fellow, and an undergraduate degree in Chemical Engineering from the Massachusetts Institute of Technology.

Fredrik NybergCEO, APACMed

Fredrik brings 30 years’ experience in the medical technology industry, 24 of which were spent in Asia-Pacific. He has worked across the region and lived in Singapore, Malaysia and Japan.

He has a background in both senior strategic consulting roles and in operational sales, marketing and general management positions.

Fredrik has also worked extensively with start-up medical technology companies both as advisor and as venture capitalist. He was mostly recently Senior Director and medical technology Practice Lead at Quintiles Consulting, based in Singapore.

He began his career in Asia with Ohmeda, now separate units of GE Healthcare, Beston Dickinson and Baxter

Fredrik holds a BSc from Gothenburg University, Sweden, and an MBA from Henley Management College, UK.

43


Bruno OcchipintiDirector of Strategy and New Business Development, Philips Healthcare Asia Pacific

Bruno Occhipinti is Director of Strategy and New Business Development for Philips APAC. His role is to launch and accelerate new digital health initiatives, in primary care for emerging markets, wearables, and chronic-care management solutions. He also drives the open innovation agenda to foster engagement with MNCs, startups / accelerators, and NGOs. Previously in Amsterdam, Bruno conducted management consulting projects for Philips Executive Committee. Prior to that in Seoul, he handled corporate development activities for the renewable energy venture of Samsung, after his role as Global Strategist in Samsung HQ. Beforehand, he also led several roles in pre-sales, product management, and consulting in business intelligence software for Hyperion (now Oracle) across Asia and Europe. He holds an MBA from the Wharton School.

Paul Ong Jau LuengSenior Consultant Cardiologist and Director of Invasive Cardiac Laboratory in the Department of Cardiology

Dr Paul Ong graduated from University of Cambridge in 1990 and obtained hisspecialist cardiology training in London and worked there as a consultantcardiologist. After 23 years in UK, he relocated to Singapore in 2009.

He is currently Head of Interventional Cardiology Services at Tan Tock SengHospital. His main interests are in primary PCI, TRI, DCB, BRS and intravascularimaging with over 50 international publications in his field of interests.

He is also the organising chairman of the Asia Primary Angioplasty Congress.

Ai Hua OngPresident, ONE Johnson & Johnson Southeast Asia

Ong Ai Hua is currently the President of One J&J Southeast Asia overseeing the business in the cluster, working in close collaboration with the Asia Pacific Company Group Chairs and providing one J&J face to external stakeholders.

Prior to her current position, Ong Ai Hua was the Integration & Business Transformation Leader for One J&J Southeast Asia and a member of the One J&J Southeast Asia Leadership Team, a role she began in 2014. Ai Hua was responsible for leading and shaping a smooth transition for the Southeast Asia countries into the ‘One J&J’ structure. From 2009, Ai Hua was Vice President for MD&D in South Asia, which includes India and Southeast Asia, and head of Ethicon surgical business for Asia Pacific. With more than 23 years with J&J, Ai Hua began her career with Johnson & Johnson Medical Singapore in 1990 as a Product Specialist. She progressed from sales and marketing positions in Singapore and then to general management responsibilities for a cluster of businesses, first in Singapore, then to China, South Asia and Asia Pacific.

Her career highlights include the successful turnaround of China Ethicon Surgical business in 2006-2009; the acquisition of Bioseal, the first J&J acquisition of a medical device company in China & Asia Pacific; and she was a key member of the incubation team for China Innovation Centre in Suzhou. She was involved in the pioneering phase of capabilities build-up and led the development of two market appropriate product lines for emerging markets.

Before joining J&J, Ai Hua worked for Sony International in the International Procurement Office. Ai Hua holds a BSc in Microbiology and Biochemistry and an MBA from the National University of Singapore (NUS).

Ai Hua is an active volunteer for charitable causes in Singapore. In addition to being chair of J&J’s Asia Pacific Contributions Committee, she is a council member of the Dover Park Hospice and a committee member of healthy start child development program for Beyond Social Services, who supports children from disadvantaged families.

Ai Hua is married to a pilot and, in her rare spare time, is a water sports, hiking and cooking enthusiast.

44


Stephen OoiSenior Executive Advisor, Zimmer Biomet

Stephen H. L. Ooi was appointed Senior Executive Advisor, Asia Pacific of Zimmer Biomet in June 2015. Prior to his current appointment, he served as President, Asia Pacific of Zimmer Holdings and was responsible for the overall operations, sales, marketing and distribution of products and business development in the Asia Pacific region. Stephen was also a Member of Zimmer Executive Operating Committee from January 2002.

Stephen joined Zimmer in 1986 as Regional Manager for Korea, Indonesia andPakistan. He was then promoted to Regional Managing Director, Asia in 1987, Vice President, Asia Region in 1992, President, Australasia in 2001 and subsequently President, Asia Pacific.

Before joining Zimmer, Stephen worked for Johnson & Johnson from 1981 to 1986 as Manager for the Pharmaceutical and Professional Dental businesses inSingapore. Prior to that, Stephen worked in a British trading company, RankO’Connors, responsible for a range of OTC Pharmaceutical, Opthalmic and Dental Products as well as fast moving consumer products.

Stephen has more than 30years of experience in the medical device andmusculoskeletal business and has a wealth of experience in sales, salesmanagement, marketing, business development and general management.

Stephen holds a Bachelor’s degree in Pharmacy with First Class Honours from the University of Singapore and an M.B.A. from the National University of Singapore.

Lorraine Parker-CleggVice President, Human Resources, Asia-Pacific, Medtronic

Lorraine Parker-Clegg has developed a successful Human Resources (HR) career from her formative years in competitive team sports and extensive sales background. Currently as the VP, HR Asia Pacific at Medtronic, Lorraine works across multiple, diverse cultures in a fast paced environment. Lorraine has a diverse international background and US experience.

During her 16 years at Bristol Myers Squibb (BMS), she led trade launches for the Consumer Products Division in Russia, Poland, Czech Republic, and Hungary and was instrumental in establishing a trade marketing department for the group. She later transferred to HR, assuming a variety of roles with increasing leadership responsibility across the UK, Ireland, Scandinavia, Central/Eastern Europe, EMEA, and the U.S. Across multiple sectors (Including consumer, pharma, med tech and aerospace), her notable accomplishments include: strategy & workforce planning; organizational design & transformational change; multi-cultural/unit management; talent acquisition & management; M&A and integration; and outsourcing partnership development.

Originally from the UK, Lorraine graduated from Sheffield Hallam University with a Bachelor of Arts degree in Sport Studies. She completed a Post Graduate Certificate in Management and has a Diploma in Personnel Management awarded with merit, from Oxford Brookes University. Lorraine is also a fellow of the Chartered Institute of Personnel and Development. Lorraine played field hockey for her home country and had served as a member of the board of directors for Special Olympics Massachusetts.

Gary PrudenWorldwide Chairman of Medical Devices and Executive Vice President, Johnson & Johnson

Gary J. Pruden is Worldwide Chairman of Medical Devices and Executive Vice President for Johnson & Johnson, also serving on the corporation’s Executive and Management Committees. Gary assumed leadership responsibility for the global businesses of surgery, orthopaedics, and cardiovascular specialty under the Medical Devices Companies of Johnson & Johnson in May 2015. In this role, he leads the Medical Device Group Operating Committee with responsibility for all commercial, R&D, operations, quality, and the functional groups that support the medical devices organization.

45


Tran QuanVice President Regulatory Affairs, APACMed

Tran Quan has 29 year of healthcare industry experience. She spent initial years in hospital services specializing in Clinical Pharmacy, Purchasing, Retail and Outpatient Pharmacy. She has held Asia Pacific regional positions inpharmaceutical companies such as Eli Lilly and GlaxoWellcome (now GSK) and was the Director of Clinical and Regulatory Affairs at Johnson & Johnson Medical Asia Pacific for more than nine years pioneering premarket registration work on breakthrough device technologies such as Drug Eluting Stents. She was the Vice President of Quality Assurance & Regulatory Affairs for Asia Pacific, GE Healthcare prior to joining APACMed as the Vice President of Regulatory Affairs.

She has played an active role in the organizing of various Asia Pacific ClinicalResearch & Regulatory Conferences such as Asian Clinical Trial Conference &Asian Harmonization Working Party Conference. She also led the inaugural AHWPRAPS Conference and several AHWP Annual meetings in the past decade.

Quan is currently the Vice Chair of AHWP engaged in dialogue with regulators and industry, contributing to the Medical Device Regulatory harmonization and convergence in the Region.

She graduated with a MSc in Clinical Pharmacy from The London School ofPharmacy, UK with a Foreign Commonwealth Office scholarship.

Sangita ReddyExecutive Director, Operations, Apollo Hospitals GroupMs. Sangita Reddy is executive director, operations at Apollo Hospitals Group, the largest hospital network in Asia with more than 9,000 beds in 44 locations. With responsibilities that involve policy, growth and strategy, Ms. Reddy is pivotal in directing the group’s operations.In addition, under her stewardship the Apollo Hospitals in Hyderabad has emerged as Asia’s first Health City. It has done so by introducing multi-dimensional holistic healthcare to India.Ms. Reddy’s inputs are central to the structure and values of the Apollo Culture. She leads the Human Resources and IT functions across the group, with responsibilities extending to all divisions of hospitals within the group. She has also been instrumental in extending community-based hospital projects, with a special focus on rural areas. One of her initiatives has been Apollo Reach, which aims to build a string of secondary care hospitals in rural areas across India.For more than 20 years, Ms. Reddy has worked in multiple segments of the healthcare sector. She has presented at several international forums including the World Health Congress and Pacific Summit. In doing so, she has earned the respect of international healthcare leaders and has influenced the development of healthcare information technology industry.

Nawal RoyFounder and CEO, Holmusk

Holmusk is a global digital health and data analytics company, focused on solving complex problems in healthcare for chronic diseases. We believe in “early detection, early intervention”.

We build innovative, scalable and cost-effective digital behaviour change programs that combine cutting-edge clinical research, technology and design to nudge people towards sustainable changes for better health. We develop powerful predictive algorithms that offer actionable insights for personalised care and population health management. We are based in Singapore and USA.Nawal, has deep experience in working across North America, Asia, Middle East, Europe and South Africa in the financial and healthcare sector.. He has been deeply involved in business development and platform building throughout Asia and North America. Before Holmusk, he was a Junior Partner leading Banking/Risk Practice Service line in McKinsey& Company Singapore office and senior banking experience at Credit suisse and deutsche bank.

46


Brent ScottPresident, Stryker Corporation

Brent is the President of Stryker Asia Region, based in Singapore. He was previously the Vice President of Value Business, International and before that, was Vice President of Marketing for Emerging Markets, and Asia Pacific from Oct 2006 to Mar 2013.

He has joined Stryker in Mar 1997 and started off as the General Manager in Victoria and worked his way up to the Managing Director for Australia and New Zealand from Oct 2002 to Oct 2006.

Prior to joining Stryker, he was with United States Surgical Corporation as the Director of Sales and Marketing in Australia and New Zealand from Jan 1995 to Mar 1997.

Brent holds a Master’s degree in Business Administration from Swinburne University of Technology in 2000 and a Bachelor’s degree of Applied Science from Phillip Institute of Technology in 1985.

Ross D. SeganChief Medical Officer, Medical Devices, Global Medical Affairs, Research and Development, Johnson & Johnson

Ross “Rusty” Segan provides thought leadership and advances the capability of medical affairs in the areas of new product development, life cycle management, and evidence generation strategies, as well as overseeing medical input into new product development and external innovation.Rusty joined J&J in 2013 as Vice President, Office of Science and New Technology. Prior to J&J he was Group Chief Medical Officer for the Surgical Solutions at Covidien. Rusty was a Major in the United States Army where he served in support of Operation Enduring Freedom and was Chief of Minimally Invasive Surgery and Acting Assistant General Surgery Residency Program Director at Tripler Army Medical Center in Hawaii.

Rusty earned his medical degree at UMDNJ-Robert Wood Johnson Medical School in New Jersey. He also received a Masters of Business Administration from the New York University Stern School of Business.

Amit ShankerChief Medical Officer, Asia Pacific, Middle East & Africa, Boston Scientific

Dr. Shanker is the Chief Medical Officer for Boston Scientific Corporation in Asia, Australia, Middle East and Africa heading Strategic Medical Affairs, Health Economics & Reimbursement. He currently serves as Chair of the Medical and Clinical Affairs committee for the Asia-Pacific Medical Technology Association. An interventional cardiac electrophysiologist by training, he previously served as Associate Professor of Medicine at Columbia University College of Physicians and Surgeons heading The Center for Advanced Arrhythmia Medicine of the New York Presbyterian Health Care System having performed 4500 surgeries with outcomes in the top 1 percentile per the US National Cardiovascular Device Registry. In addition to his clinical experience, he was involved in shaping US health policy in matters surrounding reimbursement, regulatory affairs, and government affairs engaging the FDA, CMS, AHRQ, US National Quality Forum, the American Medical Association, the American College of Cardiology, the Heart Rhythm Society, and the Society for Cardiac Angiography and Interventions. He has published or presented 75+ papers/abstracts and delivered 150+ presentations across 5 continents. He was awarded the Ruth Kirschstein Award by the NIH in 2003 for his basic science research on Connexin43.

Dr Shanker completed a 6-year accelerated B.S/M.D. Program with Penn State/Thomas Jefferson University, his internal medicine residency at Brown University, cardiovascular medicine and electrophysiology training at the Washington University School of Medicine in St Louis, and a research fellowship at the National Institute of Health.

47


Harvinder SinghDivisional Vice President, Asia Pacific and Japan, Abbott Vascular

Harvinder Singh heads Abbott Vascular’s Asia Pacific and Japan business and is based in Singapore. Harvinder has been with Abbott for 15 years and in the healthcare industry for 25 years. He has worked in both medical device and pharmaceutical industry thru his career.

Prior to joining Abbott, Harvinder worked for Eli Lilly Ranbaxy in India and lead the marketing of the anti-infectives portfolio. He has worked in sales, marketing, sales training, regional marketing, strategy and planning functions. Harvinder has deep understanding & experience in key Asian markets as he has lived and worked in Delhi - India, Tokyo - Japan, Shanghai – China, Hong Kong and now Singapore.

His educational background includes an undergraduate degree in Chemistry and Biology, and an MBA in Marketing. He has attended various management development programs in the US including the Program for Leadership development at the Harvard Business School. Prior to his current role, Harvinder was President of Abbott Vascular Japan and board member of Abbott Vascular & Abbott Japan and served on the board of the American Medical Device and Diagnostics Manufacturer’s Association of Japan (AMDD).

Simranjit SinghSenior Director of Strategies Planning and General Manager, Medical Devices and Diagnostics, Asia Pacific, QuintilesIMS

Simranjit Singh leads the process to understand, synthesize and communicate market trends, client needs, and competitive intelligence in Asia Pacific. He provides thought leadership on key market events and collaborates with Quintiles’ global and Asia Pacific leadership teams to incorporate market and competitive intelligence into strategic approaches for the region.

He also leads Quintiles Medical Devices & Diagnostics business in Asia Pacific, and has been instrumental in putting together Quintiles’ strategic partnerships with several medical device companies. Mr. Singh also serves as chairman for BioSingapore, an industry association that plays an integral role in developing Singapore’s biomedical sector.

Mr. Singh holds a bachelor’s degree in biomedical sciences from the National University of Singapore and earned his MBA from the Graduate School of Business, University of Chicago. He also has a graduate diploma in bio-entrepreneurship from the University of Pennsylvania.

48


Glenn SnyderMedical Technology Segment Leader, Deloitte’s San Francisco office

Glenn Snyder is a Principal with Deloitte Consulting, LLP in the US. He leads Deloitte’s Medical Technology practice globally. Glenn has been serving the life sciences and healthcare industry as a consultant since 1989 and has been with Deloitte since 1995, tackling issues and opportunities across the healthcare value chain over the course of his career, including the payor and provider sectors.

Glenn’s expertise is within strategy for the life sciences sector, with deep experience in medical technology, biotech and specialty pharmaceuticals. He has helped clients:improve net reimbursement, articulate product economic value, launch new products, improve market access and rationalize distribution networksexpand in new/emerging marketsnavigate changes in the healthcare ecosystem (including those specific to health reform) by modifying their commercial modeldevelop tangible growth plans that incorporate maturity aspirations, external pressures and internal development expectationsgrow through innovation of customer solutions as well as acquisitions

An eminent speaker and thought leader, Glenn has presented at notable conferences, including AdvaMed, Lifesciences Alley, Medical Device Strategic Pricing, and Analytical and Lifesciences Systems Association. He has also published articles and whitepapers through Deloitte University Press, and industry journals.

Glenn holds a Master of Business Administration in Finance and Strategic Management from the Wharton School of the University of Pennsylvania, a Master of Science in Engineering from the University of Southern California, and a Bachelor of Science in Engineering from Cal Poly, San Luis Obispo.

Elisabeth StaudingerPresident Asia Pacific, Siemens Healthineers

Elisabeth Staudinger studied sinology and economics in Vienna, Nanjing, and Beijing and holds a master’s degree in both subjects. Directly after graduating from college, she began her career with Siemens in 1998 at Global Procurement and Logistics in Munich.

From 1999 until 2002, she was in charge of Siemens Procurement and Logistics Services in Shanghai. After holding several management positions at Siemens Healthcare in Germany and China, she moved to Forchheim, Germany, in January 2009, where she assumed the role of Chief Executive Officer of the Refurbished Systems Business Unit. In November 2013, she assumed the position of Healthcare Region Lead for ASEAN-Pacific in Singapore and was promoted to President Asia Pacific in October 2015.

Elisabeth Staudinger is married and has one son.

49


Tan Sze WeeExecutive Director of A*STAR’s Science and Engineering Council (SERC)

Prof Tan’s career in A*STAR began in 2009, where he held the appointment of Programme Director of the Medical Technology initiative in SERC. His next appointment was as Director of SERC’s Strategic Initiatives, where he oversaw all SERC cluster-led R&D development. He also provided leadership for SERC’s cross-cutting programmes such as the Thematic Research Programme and the Joint Laboratories programme with the local universities and concurrently spearheaded the Healthcare and Lifestyle (H&L) Programme in A*STAR.

In October 2012, Prof Tan was promoted to Deputy Executive Director in the Biomedical Research Council (BMRC). His experience with the SERC RIs enabled BMRC to engage companies in these industry sectors holistically, cross-promoting the multi-disciplinary capabilities available at both Councils to meet the needs of companies. He helped to pave the way for growth of A*STAR’s engagements with companies in the Food & Nutrition, Medical Technology and Consumer Care sectors with leading MNCs like GE Healthcare, Nestle, Coca Cola and P&G.

Prof Tan is Adjunct Professor at Nanyang Technological University’s School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine, as well as an Adjunct Associate Professor at Duke-NUS Graduate Medical School Singapore. He is also Chairman of the Singapore Stanford Biodesign Steering Committee, and member of the steering committee of Rehabilitation Research Institute of Singapore.

Prof Tan was formerly the Managing Director and Chief Executive Officer of Rockeby Biomed Limited. Prior to joining Rockeby, he was the Asia-Pacific Associate Regional Medical Director (Asia Regional Office) for Mead Johnson Nutritionals, a division of Bristol-Myers Squibb Company from 1997 to 2001.

Prof Tan was a former Nominated Member of Parliament of Singapore. Prof Tan is a member of the Corporate Technology Platform Scientific Advisory Board for Procter and Gamble, as well as a member of Singapore National Eye Centre’s Ophthalmic Technologies Incubator Advisory Board.

Prof Tan is a Board Member to DSO National Laboratories and the Singapore Maritime Institute.

Prof Tan is also council member of the Singapore Medical Association (SMA), as well as board of director for SMA Pte Ltd and SMA Charity Pte Ltd.

Prof Tan is currently the Chairman of the Advertising Standards Authority of Singapore’s Executive Committee. He is also co-chair to the MND Inter-Ministry Committee on Food Security R&D Workgroup. Prof Tan is also the Treasurer of the YMCA, and a member to Consumer Association of Singapore (CASE) Central Committee.

Prof Tan graduated with a Bachelor of Medicine and a Bachelor of Surgery from the National University of Singapore, and attained his Masters of Business Administration from Warwick University, UK. He attended the Stanford Executive Programme at the Stanford Graduate School Business. He is an affiliate member of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, UK. He is a registered medical practitioner with the Singapore Medical Council and the Hong Kong Medical Council.

50


Stanley SuPresident, B.Braun China

Stanley SU (born 1 March1969) is the president of B. Braun Greater China, who works at B.Braun since year 2006.

Stanley was graduated from the China Pharmaceutical University (CPU) in 1991, he worked for Xian Janssen Pharmaceutical Ltd as a saes rep. in 1992 and later Johnson & Johnson Medical (China) Ltd. as the franchise director of DePuy before joining B. Braun. When he joined B.Braun, he served as the General Manager of Hospital Care Division, and he was appointed as president of B. Braun China since July 2014.

Stanly Su is a MBA from Rutger school of business of State University of New Jersey and received the diploma of GMP from Harvard Business School.

Stanley is devoted himself to executing the vision of B. Braun to protect and improve the health of people in China, and meanwhile adhering the company value of “ share expertise” through dialogs with customers and partners continuously .

Jacob ThomasGroup Medical Advisor, Ramsay Sime Darby Health Care and President, Association of Private Hospitals of Malaysia (APHM)

Dato’ Dr Jacob Thomas, a medical doctor, has a vast experience in hospital management, having served in various capacities at Subang Jaya Medical Centre, including as its Executive Director from 1998 till 2006. He is currently the Group Medical Advisor of Ramsay Sime Darby Health Care.

Dr Jacob Thomas has also been the President of the Association of Private Hospitals of Malaysia (APHM) since 2008 and is a member of the Consultative Panel of Healthcare sector of the Malaysia Productivity Corporation (MPC). He serves as a Councilor of the Malaysian Society for Quality in Health (MSQH), a member of the Malaysia Healthcare Travel Council (MHTC). Dr Thomas today works closely with various NGOs and Government agencies to promote Malaysian Healthcare both locally and internationally. He is a Steering Committee Member of the National Key Economic Areas (NKEA) for Healthcare. An initiative of the Malaysian Government.

Since July 2013, he holds the position of Chairman of the newly formed Ramsay Sime Darby Health Care Group.

Dr Jacob has been appointed to the Board of Directors of Joint Commission International (JCI) effective 20 June 2014.

Joselito VitalPublic Health Consultant, German International Agency

A medical doctor with a Bachelor of Science and Masters degree in Public Health from the University of the Philippines. He had various post-graduate courses like Quality Management in International Health from the University of Heidelberg Germany; Vaccinology from Pasteur Merieux Connaught in Lyon France and Health Program Monitoring and Evaluation from the Asian Management Institute in Bangkok Thailand among others. Dr. Vital have been doing public health and clinical work for the past 25 years. Presently he serves as a Public Health Consultant for the German International Agency for 11 years now although he has some leverage to engage in short-term consultancy work with other development agencies and organizations like The World bank, Asian Development bank, USAID, AECID, UNFPA, Social Impact, Childfund, Chemonics and RTI International doing public health program management, qualitative research, health program performance evaluation, grant proposal development and workplace wellness program development. He had done speaking engagements in local and international health conferences before and among which was the 2015 Asia Pacific MedTech Forum in Singapore.

51


Christopher L. WhiteSenior Executive Vice President, General Counsel, AdvaMed

Christopher L. White, Esq. the Chief Operating Officer, General Counsel and Secretary of the Advanced Medical Technology Association (AdvaMed).

Mr. White serves as the Association’s Chief Legal Officer and manages AdvaMed’s Legal Committee to develop and promote legal policy positions enhancing patient access to medical technology. Mr. White also leads the Association’s global working groups on legal policy and compliance, including over 1500 in-house medtech lawyers. He led the multinational negotiating team to draft the Kuala Lumpur Principles, harmonizing industry Codes of Ethics in Asia. He is a frequent speaker on health law and policy issues, and serves as a frequent speaker and author on industry legal and compliance issues.

Mr. White is a graduate of Wake Forest University where he studied cell biology, and Catholic University Law School.

He is an avid sailor, cyclist and beekeeper.

Yan Lin Lye Business Development Manager, Cambridge Consultants

Yan Lin graduated at the top of her Biomedical Engineering class at the University of Southern California, USA with a specialization in Electrical Engineering. She also won only 1 of 22 Global Scholars designations in the entire USC class for her study of the international application of engineering principles within regulatory systems.

She also holds a Masters in Bioscience Enterprise from the University of Cambridge, UK where her thesis was on the analysis of successful engagement models of Western pharmaceutical companies in China.

Previous experience included working at DNA Electronics which was developing innovative next generation sequencing platforms and various point of care molecular diagnostic platforms. There she set business and regulatory strategy and more broadly she helped take care of their business interests.

She also helped Credo Biomedical to set business and regulatory strategy for innovative immunoassay and molecular diagnostic platforms meant for developed and developing world applications

Lani YapPatient Speaker

Lani is an example of someone who has benefited from technology in the health care industry.

She underwent a Total Hip replacement 6 years ago and as a result she was able to continue to pursue her passion which is dancing at a competitive level.

The most fascinating part of her story is the speed at which she was able to attain this post op.

52


MAKING AN IMPACT ON THE WORLD OF HEALTH. Across the healthcare continuum, BD is known for medical technology, devices and laboratory equipment—from medication management and parenteral drug delivery to diagnostics and solutions for clinical research. What may be less known about us is the difference BD has made in untold millions of lives in ways as diverse as helping enable inoculation of children for the final eradication of polio, identifying infectious organisms and providing the research tools to help advance the discovery of a vaccine for AIDS. Today our associates serve every corner of the world, united by one purpose: advancing the world of health. And through our extensive experience with partnerships, our depth of insights and exceptionally broad portfolio of solutions from discovery to delivery, we aim to make an even greater difference in human health across generations. Discover the difference one company can make. Discover the new BD.

© 2016 BD. BD and the BD Logo are trademarks of Becton, Dickinson and Company. MC5917

Learn more about the Difference of One at bd.com/BD1-New

BDIG-BrandDo1AsiaAdResize16-21386-d1.indd 1 9/27/16 3:52 PM

53


SPONSOR LISTING

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Platinum Sponsor

MAKING AN IMPACT ON THE WORLD OF HEALTH. Across the healthcare continuum, BD is known for medical technology, devices and laboratory equipment—from medication management and parenteral drug delivery to diagnostics and solutions for clinical research. What may be less known about us is the difference BD has made in untold millions of lives in ways as diverse as helping enable inoculation of children for the final eradication of polio, identifying infectious organisms and providing the research tools to help advance the discovery of a vaccine for AIDS. Today our associates serve every corner of the world, united by one purpose: advancing the world of health. And through our extensive experience with partnerships, our depth of insights and exceptionally broad portfolio of solutions from discovery to delivery, we aim to make an even greater difference in human health across generations. Discover the difference one company can make. Discover the new BD.

© 2016 BD. BD and the BD Logo are trademarks of Becton, Dickinson and Company. MC5917

Learn more about the Difference of One at bd.com/BD1-New

BDIG-BrandDo1AsiaAdResize16-21386-d1.indd 1 9/27/16 3:52 PM

Alcon is the global leader in eye care. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our products touch the lives of more than 260 million people living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. We do this through innovative products, partnerships with eye care professionals and programs that enhance access to quality eye care. We have firsthand experience working in developing markets where loss of sight means loss of productivity and community connection. By reducing the number of blind individuals to 24 million people globally by 2020, the economic gain would be $102 billion1. The community and emotional gain is incalculable.

Website: www.alcon.com

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues.

Website: www.bd.com With over 55,000 employees in 64 countries, B. Braun is one of the world’s leading providers of healthcare solutions, specialising in solutions related to infusion therapy, orthopaedics, neurosurgery, anaesthesia, extracorporeal blood treatment, spine surgery, diabetes care, clinical nutrition, wound management, infection prevention and surgical technologies. Around the world, B. Braun’s products and services are trusted for their high quality and safety standards by medical professionals. Through its world-renowned Aesculap Academy, B. Braun advances training and education for medical practitioners.

Website: www.bbraun.com

Gold Sponsors

54


Gold Sponsors

Deloitte provides audit, consulting, financial advisory, risk advisory, tax and related services to clients spanning multiple industries. Deloitte serves four out of five Fortune Global 500® companies through a globally connected network of member firms in more than 150 countries bringing world-class capabilities, insights, and high-quality service to address clients’ most complex business challenges.

In Southeast Asia, our Life Sciences practice has vast experience in every segment of the industry from consumer health to medical devices. Through the combination of our local industry knowledge and the expertise of our global network, we have the right combination of experience and capability to deliver the value to our global and regional clients.

Website: www.deloitte.com

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and economic expertise to address the complex challenges faced by healthcare systems today. Let’s take healthcare Further, Together. Learn more at Medtronic.com.

Website: www.medtronic.com

Terumo Corporation was founded in 1921 by several scientists and doctors, including Dr. Shibasaburo Kitasato, to produce clinical thermometers in Japan.

With our corporate mission of “Contributing to Society through Healthcare,” we are doing business through three companies: The Cardiac and Vascular Company, the General Hospital Company and the Blood Management Company.

We work proactively to stably provide high-quality medical devices and services for the benefit of patients and medical settings in over 160 countries, while also developing solutions to advance the practice of healthcare.

Website: www.terumo.com

Founded in 1927 and headquartered in Warsaw, Indiana, USA, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues.

We have operations in more than 25 countries globally and sell products in more than 100 countries.

SPONSOR LISTING

55


SPONSOR LISTING

Boston Scientific is a global medical technology company that develops more than 13,000 less-invasive products that improve patient outcomes increase efficiencies and reduce costs. For more than 35 years, the company has been transforming lives by focusing on addressing the most pressing clinical needs in the specialties it serves, pursuing excellence and collaborating deeply with healthcare professionals around the globe to help solve their toughest challenges.

For more information about how Boston Scientific is advancing science for life, visit www.bostonscientific.com and connect with us on Twitter and Facebook.

Silver Sponsor

Bronze Sponsors

INC Research is a leading global contract research organization (“CRO”) providing the full range of clinical services for the biopharmaceutical and medical device/diagnostic industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple therapies, INC Research connects Sponsors, clinical research sites and patients to accelerate the delivery of new products to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.

Website: www.incresearch.com QuintilesIMS Medical Device & Diagnostics provides a comprehensive range of regulatory & clinical development services for Medtech companies to achieve commercial success. These services include strategic regulatory assessments, proof-of-concept & pivotal clinical studies, post marketing & commercialization support. We utilize an experienced medical device operations team with best in class technology & processes to deliver high quality services. In Asia Pacific, we have operations in Greater China, Japan, South Korea, Australia and South East Asia. QuintilesIMS has earned preferred vendor status with several of the world’s largest medical device companies.

Website: www.quintiles.com

To us, it’s about much more than packages. That’s why we have dedicated teams of healthcare specialists, trade compliance experts, and facilities around the world. All working with advanced customs clearance processes to make international distribution and shipping smoother for your business. And with our temperature-sensitive packaging expertise, active monitoring, and intervention capabilities, we’re helping to deliver critical products safely to the people who need them. From figuring it out to getting it done, we’re here to help.

56


One change can change everythingAt Deloitte, we understand that even the smallest change can disrupt your entire business. Deloitte has the experience, insight and knowledge to help you identify upcoming changes, plan for them and seize the opportunities they present.

Are you ready? We know we are. Visit www2.deloitte.com/sg to find out more.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see www.deloitte.com/sg/about to learn more about our global network of member firms.

© 2016 Deloitte & Touche LLP

57


One change can change everythingAt Deloitte, we understand that even the smallest change can disrupt your entire business. Deloitte has the experience, insight and knowledge to help you identify upcoming changes, plan for them and seize the opportunities they present.

Are you ready? We know we are. Visit www2.deloitte.com/sg to find out more.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. Please see www.deloitte.com/sg/about to learn more about our global network of member firms.

© 2016 Deloitte & Touche LLP

www.medtechforum.asia

See you at

ASIA PACIFICMEDTECH FORUM

2017!

58


Supporting Organisations

Managed By

Organised by

Held in

Supported by

programme book - the voice of medtech in asia · following the success of last year’s medtech...

Documents